# EDGAR Filing Document

**Accession Number:** 0001725255
**File Stem:** 0001628280-26-027965
**Filing Date:** 2026-4
**Character Count:** 215992
**Document Hash:** ca0966749d04ac2e75cef090ca09e10e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-027965.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001628280-26-027965

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 22

**CONFORMED PERIOD OF REPORT**: 20260618

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AdaptHealth Corp.
- **CENTRAL INDEX KEY:** 0001725255
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HOME HEALTH CARE SERVICES [8082]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 823677704
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38399
- **FILM NUMBER:** 26908458

**BUSINESS ADDRESS:**
- **STREET 1:** 555 EAST NORTH LANE
- **STREET 2:** SUITE 5075
- **CITY:** CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
- **BUSINESS PHONE:** 610-424-4515

**MAIL ADDRESS:**
- **STREET 1:** 555 EAST NORTH LANE
- **STREET 2:** SUITE 5075
- **CITY:** CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DFB Healthcare Acquisitions Corp.
- **DATE OF NAME CHANGE:** 20171213

?xml version='1.0' encoding='ASCII'? ahco-20260428

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_______________________

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

_______________________

Filed by the Registrant ⌧

Filed by a Party other than the Registrant □

Check the appropriate box:

□ Preliminary Proxy Statement

□ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

⌧ Definitive Proxy Statement

□ Definitive Additional Materials

□ Soliciting Material under §240.14a-12

**AdaptHealth Corp.**

(Name of Registrant as Specified in Its Charter)

**N/A**

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

⌧ No fee required.

□ Fee paid previously with preliminary materials.

□ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**NOTICE OF ANNUAL MEETING OF STOCKHOLDERS**

To Be Held On June 18, 2026

Dear Stockholders of AdaptHealth Corp.:

You are cordially invited to attend the Annual Meeting of Stockholders of AdaptHealth Corp. The meeting will be held on June 18, 2026 at 10:30 a.m. Eastern Time. The Annual Meeting will be a completely virtual meeting of stockholders conducted via live audio webcast. You will be able to attend the Annual Meeting by visiting www.virtualshareholdermeeting.com/AHCO2026. We are holding the Annual Meeting for the following purposes, which are more fully described in the proxy statement accompanying this notice:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)To elect nine directors to serve for one-year terms;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)To approve, in a non-binding advisory vote, the compensation of our named executive officers as described in this proxy statement ("**say-on-pay**").

The record date for the Annual Meeting is April 24, 2026. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof. The Notice of Internet Availability of Proxy Materials ("**Notice**"), proxy statement and form of proxy are being distributed and made available on the Internet on or about April 28, 2026.

By Order of the Board of Directors

---

| |
|:---|
| /s/ Richard Rew |
| Richard Rew |
| Secretary |
| April 28, 2026 |

---

**Whether or not you expect to attend the Annual Meeting, please vote at your earliest convenience by following the instructions in your proxy materials.**

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| <u>[QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND THE ANNUAL MEETING](#icb8b7d474fb54376885edd8b3dcbbb72_16)</u> | <u>[2](#icb8b7d474fb54376885edd8b3dcbbb72_16)</u> |
| <u>[CERTAIN DEFINED TERMS](#icb8b7d474fb54376885edd8b3dcbbb72_19)</u> | <u>[6](#icb8b7d474fb54376885edd8b3dcbbb72_19)</u> |
| <u>[PROPOSAL NO. 1 — ELECTION OF DIRECTORS](#icb8b7d474fb54376885edd8b3dcbbb72_22)</u> | <u>[7](#icb8b7d474fb54376885edd8b3dcbbb72_22)</u> |
| <u>[PROPOSAL NO. 2 — RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM](#icb8b7d474fb54376885edd8b3dcbbb72_25)</u> | <u>[11](#icb8b7d474fb54376885edd8b3dcbbb72_25)</u> |
| <u>[PROPOSAL NO. 3 — SAY-ON-PAY](#icb8b7d474fb54376885edd8b3dcbbb72_28)</u> | <u>[13](#icb8b7d474fb54376885edd8b3dcbbb72_28)</u> |
| <u>[INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE](#icb8b7d474fb54376885edd8b3dcbbb72_31)</u> | <u>[14](#icb8b7d474fb54376885edd8b3dcbbb72_31)</u> |
| <u>[REPORT OF THE AUDIT COMMITTEE](#icb8b7d474fb54376885edd8b3dcbbb72_34)</u> | <u>[19](#icb8b7d474fb54376885edd8b3dcbbb72_34)</u> |
| <u>[EXECUTIVE AND DIRECTOR COMPENSATION](#icb8b7d474fb54376885edd8b3dcbbb72_37)</u> | <u>[20](#icb8b7d474fb54376885edd8b3dcbbb72_37)</u> |
| <u>[STOCK PERFORMANCE GRAPH](#icb8b7d474fb54376885edd8b3dcbbb72_40)</u> | <u>[22](#icb8b7d474fb54376885edd8b3dcbbb72_40)</u> |
| <u>[COMPENSATION DISCUSSION & ANALYSIS](#icb8b7d474fb54376885edd8b3dcbbb72_43)</u> | <u>[23](#icb8b7d474fb54376885edd8b3dcbbb72_43)</u> |
| <u>[CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS](#icb8b7d474fb54376885edd8b3dcbbb72_109)</u> | <u>[55](#icb8b7d474fb54376885edd8b3dcbbb72_109)</u> |
| <u>[SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT](#icb8b7d474fb54376885edd8b3dcbbb72_112)</u> | <u>[55](#icb8b7d474fb54376885edd8b3dcbbb72_112)</u> |
| <u>[SOLICITATION OF PROXIES](#icb8b7d474fb54376885edd8b3dcbbb72_115)</u> | <u>[60](#icb8b7d474fb54376885edd8b3dcbbb72_115)</u> |
| <u>[DELINQUENT SECTION 16(a) REPORTS](#icb8b7d474fb54376885edd8b3dcbbb72_118)</u> | <u>[60](#icb8b7d474fb54376885edd8b3dcbbb72_118)</u> |
| <u>[HOUSEHOLDING INFORMATION](#icb8b7d474fb54376885edd8b3dcbbb72_121)</u> | <u>[60](#icb8b7d474fb54376885edd8b3dcbbb72_121)</u> |
| <u>[STOCKHOLDER PROPOSALS AND NOMINATIONS](#icb8b7d474fb54376885edd8b3dcbbb72_124)</u> | <u>[60](#icb8b7d474fb54376885edd8b3dcbbb72_124)</u> |
| <u>[COMMUNICATIONS WITH THE BOARD](#icb8b7d474fb54376885edd8b3dcbbb72_127)</u> | <u>[60](#icb8b7d474fb54376885edd8b3dcbbb72_127)</u> |
| <u>[AVAILABLE INFORMATION](#icb8b7d474fb54376885edd8b3dcbbb72_130)</u> | <u>[61](#icb8b7d474fb54376885edd8b3dcbbb72_130)</u> |

---

i

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**ADAPTHEALTH CORP.**

**555 EAST NORTH LANE, SUITE 5075**

**CONSHOHOCKEN, PA 19428**

**PROXY STATEMENT**

**2026 ANNUAL MEETING OF STOCKHOLDERS**

June 18, 2026

**INFORMATION CONCERNING SOLICITATION AND VOTING**

Our board of directors is soliciting proxies for our 2026 Annual Meeting of Stockholders, or the Annual Meeting, to be held on June 18, 2026 at 10:30 a.m. Eastern Time. The Annual Meeting will be a completely virtual meeting of stockholders conducted via live audio webcast. You will be able to attend the Annual Meeting by visiting www.virtualshareholdermeeting.com/AHCO2026.

We will provide access to our proxy materials via the Internet at https://www.adapthealth.com/investorrelations, rather than in hard copy. We will mail a notice containing instructions on how to access this proxy statement and our annual report on or about April 28, 2026 to all stockholders entitled to vote at the Annual Meeting. The proxy statement, form of proxy and our Annual Report on Form 10-K for the year ended December 31, 2025 are being distributed and made available on the Internet on or about April 28, 2026.

**Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to Be Held on June 18, 2026:**

Pursuant to the rules adopted by the Securities and Exchange Commission, or the SEC, we have elected to provide access to our proxy materials, including this proxy statement and our Annual Report on Form 10-K for the year ended December 31, 2025, over the Internet. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials, or the Notice, to our stockholders of record entitled to vote at the Annual Meeting with instructions for accessing the proxy materials and voting over the Internet or by telephone. We intend to mail the Notice on or about April 28, 2026 to all stockholders entitled to vote at the Annual Meeting.

All stockholders entitled to vote at the Annual Meeting will have the ability to access the proxy materials on the website referred to in the Notice and to request to receive a printed set of the proxy materials. This makes the proxy distribution process more efficient and less costly and helps conserve natural resources. Instructions on how to access the proxy materials over the Internet or to request a printed copy of the proxy materials may be found in the Notice.

The Notice will also identify the date and time of the Annual Meeting; the matters to be acted upon at the meeting and the board of directors' recommendation with regard to each matter; a toll-free telephone number, an e-mail address, and a website where stockholders can request to receive, free of charge, a paper or e-mail copy of this proxy statement, our Annual Report on Form 10-K for the year ended December 31, 2025, and a form of proxy relating to the Annual Meeting; information on how to access and vote the form of proxy; and information on how to attend the virtual meeting and vote should stockholders choose to do so.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND THE**

**ANNUAL MEETING**

---

| | |
|:---|:---|
| ***Why did I receive these materials?*** | We have sent you these proxy materials because the board of directors (the "**board of directors**" or the "**Board**") of AdaptHealth Corp. (the "**Company**") is soliciting your proxy to vote at our Annual Meeting of Stockholders on June 18, 2026 (the "**Annual Meeting**"). These proxy materials contain information about the items being voted on at the Annual Meeting and information about us.  |
| ***How can I attend and participate in the Annual Meeting?*** | The Annual Meeting will be a completely virtual meeting of stockholders conducted exclusively via live audio webcast. You will be able to attend the Annual Meeting by visiting www.virtualshareholdermeeting.com/AHCO2026. To participate in the Annual Meeting, you will need the 16-digit control number included on your Notice, proxy card, or voting instruction card. The Annual Meeting will begin promptly at 10:30 a.m. Eastern Time on June 18, 2026. We encourage you to access the virtual meeting website prior to the start time.  |
| ***What if I have technical difficulties or trouble accessing the virtual meeting website?*** | Technicians will be available to assist you if you experience technical difficulties accessing the virtual meeting website. If you encounter any difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the virtual meeting website login page. |
| ***Who is entitled to vote?*** | The record date for the Annual Meeting is April 24, 2026. This means that holders of our Common Stock on such date are entitled to vote at the Annual Meeting. As of April 24, 2026, there were 136,054,152 shares of our common stock (the "**Common Stock**") outstanding and entitled to vote at the Annual Meeting.  |
| ***How many votes do I have?*** | Each share of our Common Stock is entitled to one vote on each matter properly submitted for stockholder action at the Annual Meeting. |
| ***What am I voting on?*** | You will be voting on the following:<br>• To elect nine directors to serve for one-year terms;<br>• To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; and<br>• To approve, in a non-binding advisory vote, the compensation of our named executive officers as described in this proxy statement ("**say-on-pay**").  |
| ***How do I vote?*** | You may vote in the following ways:<br>• ***At the Annual Meeting:*** You may vote your shares electronically at the Annual Meeting by using the control number on your Notice, proxy card, or voting instruction form and following the instructions at www.virtualshareholdermeeting.com/AHCO2026. If you have already voted previously by telephone or Internet, there is no need to vote again at the Annual Meeting unless you wish to revoke and change your vote.<br>• ***By Telephone or Internet:*** If you hold your shares in street name or in an account at a brokerage firm or bank, you may be able to vote your shares by telephone or over the Internet. Please follow the instructions on your proxy or voting instruction card.<br>• ***By Mail:*** You may vote by marking, dating and signing your proxy card and promptly returning it by mail in the enclosed envelope.  |
| ***What if I return my proxy or voting instruction card but do not mark it to show how I am voting?*** | Your shares will be voted according to the instructions you have indicated on your proxy or voting instruction card. If no direction is indicated, your shares will be voted "FOR" the election of nine director nominees to serve for one-year terms and "FOR" Proposals 2 and 3. |

---

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

---

| | |
|:---|:---|
| ***How do I change or revoke my proxy?*** | Any person signing a proxy in the form accompanying this proxy statement has the power to revoke it prior to the Annual Meeting or at the Annual Meeting prior to the vote pursuant to the proxy. A proxy may be revoked by a writing delivered to us stating that the proxy is revoked, by a subsequent proxy that is signed by the person who signed the earlier proxy and is delivered before or at the Annual Meeting, by voting again on a later date on the Internet or by telephone (only your latest Internet or telephone proxy submitted prior to the Annual Meeting will be counted), or by attendance at the Annual Meeting and voting electronically. |
| ***What does it mean if I receive more than one proxy or voting instruction card?*** | It means you have multiple accounts at the transfer agent and/or with banks and stockbrokers. Please vote all of your shares. |
| ***What constitutes a quorum?*** | Any number of stockholders, together holding at least a majority in voting power of the capital stock of the Company issued and outstanding and generally entitled to vote in the election of directors, present or represented by proxy at any meeting duly called, shall constitute a quorum for the transaction of all business. Abstentions and "broker non-votes" are counted as shares "present" at the meeting for purposes of determining whether a quorum exists. A "broker non-vote" occurs when shares held of record by a bank, broker or other holder of record for a beneficial owner are deemed present at the meeting for purposes of a quorum but are not voted on a particular proposal because that record holder does not have discretionary voting power for that particular matter under the applicable rules of the Nasdaq Stock Market and has not received voting instructions from the beneficial owner. |
| ***What vote is required in order to approve Proposals 1, 2, and 3?*** | **Proposal 1 (Election of Directors):** The nine nominees named in this proxy statement who have been nominated by the board of directors to continue to serve as directors will be elected by plurality vote. This means that the nine nominees with the most votes cast in their favor will be elected to the directorships. Votes withheld from one or more director nominees will have no effect on the election of any director from whom votes are withheld. If you do not want to vote your shares for a nominee, you may indicate that in the space provided on the proxy card or the voting instruction card or withhold authority as prompted during telephone or Internet voting. In the unanticipated event that a director nominee is unable or for good cause will not serve, the proxy will be voted for such other person as shall be designated by the board of directors to replace the nominee, or in lieu thereof, the board may reduce the number of directors.<br>**Proposal 2 (Ratification of Appointment of KPMG LLP):** This proposal requires the affirmative vote of a majority of the votes cast by the holders of our outstanding Common Stock present in person or represented by proxy at the Annual Meeting and entitled to vote on Proposal 2. Abstentions and broker non-votes will have no effect on the outcome of the proposal.<br>**Proposal 3 (Say-on-Pay):** Please note that the "**say-on-pay**" vote is only advisory in nature and has no binding effect on us or our board of directors. Our board of directors will consider Proposal 3 approved by a majority of the votes cast.  |
| ***May my broker vote my shares?*** | Brokers may no longer use discretionary authority to vote shares on the election of directors or non-routine matters if they have not received instructions from their clients. It is important, therefore, that you cast your vote if you want it to count in the approval of the election of directors (Proposal 1) and Say-on-Pay (Proposal 3). Your broker has the authority to exercise discretion with respect to ratification of appointment of KPMG LLP (Proposal 2) if it has not received your instructions for that proposal because that matter is treated as routine under applicable rules. |

---

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

---

| | |
|:---|:---|
| ***How will voting on any other business be conducted?*** | We do not know of any business or proposals to be considered at the Annual Meeting other than those set forth in this proxy statement. If any other business is properly presented at the Annual Meeting, the proxies received from our stockholders give the proxy holders the authority to vote on the matter in their sole discretion. In accordance with our bylaws, no business (other than the election of the nine nominees, Proposal 2 or Proposal 3) may be brought before the Annual Meeting, or any adjournment or postponement thereof, unless such business is brought by or at the direction of the board of directors or a committee of the board of directors.  |
| ***Who will count the votes?*** | Broadridge Financial Solutions, Inc. will act as the inspector of elections and will tabulate the votes. |

---

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 18, 2026**

**The 2026 Proxy Statement, a form of proxy and the Company's Annual Report on Form 10-K for the year ended December 31, 2025 are available at:**

https://www.adapthealth.com/investorrelations

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**CERTAIN DEFINED TERMS**

Unless the context otherwise requires, references in this proxy statement to:

"**AeroCare**" are to AeroCare Holdings, Inc.;

"**AeroCare Merger Agreement**" are to the merger agreement, dated as of December 1, 2020, by and among the Company, AH Apollo Merger Sub Inc., AH Apollo Merger Sub II, Inc., AeroCare Holdings, Inc. and Peloton Equity, LLC;

"**AdaptHealth Holdings**" are to AdaptHealth Holdings LLC;

"**BlueMountain**" are to BlueMountain Capital Management LLC and its affiliates, collectively;

"**BlueMountain Entities**" are to BlueMountain Summit Opportunities Fund II (US) L.P., BMSB L.P., BlueMountain Foinaven Master Fund L.P. and BlueMountain Fursan Fund L.P., collectively;

"**BlueMountain Board Designee Rights Letter Agreement**" are to the letter agreement, dated as of November 8, 2019, by and among the Company, AdaptHealth Holdings and the BlueMountain Entities;

"**BM Notes**" are to the promissory notes previously made by AdaptHealth Holdings to the BlueMountain Entities (or their permitted transferees), collectively;

"**Business Combination**" are to the transactions contemplated by the Agreement and Plan of Merger, dated July 8, 2019 and as amended on October 15, 2019, by and between AdaptHealth Holdings and DFB Healthcare Acquisitions Corp. ("DFB");

"**Common Stock**" are to our Common Stock, par value $0.0001 per share;

"**Deerfield**" are to Deerfield Private Design Fund IV, L.P.;

"**Deerfield Subscription Agreement**" are to the Amended and Restated Subscription Agreement, dated as of October 15, 2019, among DFB, Deerfield and RAB Ventures (DFB) LLC;

"**Exchange Act**" are to the Securities Exchange Act of 1934, as amended;

"**management**" or our "**management team**" are to our officers and directors;

"**OEP**" are to One Equity Partners VII, L.P. and its affiliates, collectively;

"**OEP Investment Agreement**" are to the investment agreement, dated as of May 25, 2020, by and between the Company, OEP AHCO Investment Holdings, LLC and solely for purposes of Section 3.10 thereof, OEP; and

"**Securities Act**" are to the Securities Act of 1933, as amended.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**PROPOSAL NO. 1 — ELECTION OF DIRECTORS**

The Board proposes the election of Gregory Belinfanti, Suzanne Foster, Kenneth A. Samet, Dr. Susan Weaver, Brad Coppens, Terence Connors, Ted Lundberg, David Williams III and Dale Wolf. The director nominees have been recommended by the Corporate Compliance and Governance Committee of the Board for election and nominated by the Board for election at the Annual Meeting.

In the unanticipated event that a director nominee is unable to or for good cause will not serve, shares that would have been voted for that nominee will instead be voted for the election of a substitute nominee proposed by us. Each person nominated for election has agreed to serve if elected. Our management has no reason to believe that any nominee will be unable to serve.

If a quorum is present and voting at the Annual Meeting, the nominees receiving the highest number of votes will be elected to our board of directors. Votes withheld from any nominee, abstentions and broker non-votes will be counted only for purposes of determining a quorum. Broker non-votes will have no effect on this proposal as brokers or other nominees are not entitled to vote on such proposals in the absence of voting instructions from the beneficial owner.

**OUR BOARD OF DIRECTORS RECOMMENDS THAT OUR STOCKHOLDERS VOTE "FOR" THE ELECTION OF EACH NAMED NOMINEE.**

The following table sets forth information with respect to the director nominees standing for election at the Annual Meeting as of April 28, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name<sup>1</sup>** | **Age** | **Position** | **Director Since** | **Committee Memberships** |
| Greg Belinfanti | 51 | Director | 2021 | Compensation, Corporate Compliance & Governance |
| Terence Connors | 71 | Director | 2019 | Audit (Chair), Corporate Compliance & Governance |
| Brad Coppens | 44 | Director | 2020 | Audit, Compensation (Chair) |
| Suzanne Foster | 56 | Director | 2024 | N/A |
| Ted Lundberg | 51 | Director | 2021 | Audit, Corporate Compliance & Governance (Chair) |
| Kenneth A. Samet | 68 | Director |  | Audit<sup>2</sup> |
| Dr. Susan Weaver | 65 | Director | 2018 | Compensation, Corporate Compliance & Governance |
| David Williams III | 53 | Director | 2020 | Compensation, Corporate Compliance & Governance |
| Dale Wolf | 72 | Director | 2019 | Audit |

---

The following is biographical information as of April 28, 2026 for each of our director nominees:

**Gregory Belinfanti** has served on our board of directors since September 2021. Mr. Belinfanti is President and a member of the Investment Committee at One Equity Partners. During his tenure at OEP, Mr. Belinfanti has worked on a

<sup>1</sup> Our Corporate Compliance & Governance Committee and the Board of Directors did not renominate Diana Nole for election to the Board of Directors and her term will expire at the conclusion of the 2026 Annual Meeting.

<sup>2</sup> Mr. Samet will join the Audit Committee effective as of the 2026 Annual Meeting if elected.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

number of investments in the healthcare and business services industries and has led many of OEP's healthcare transactions. Mr. Belinfanti is a member of the Board of Directors of Fortis Healthcare, Nuclear Care Partners, Ernest Health, and has previously been a member of the Board of Directors of The Results Companies, PS Logistics, Apollo Health Street, ArthroCare, Celltrion Healthcare, EGS, OneLink, Prodigy, Simplura Health Group, and Systagenix. Prior to joining OEP, Mr. Belinfanti served as a Vice President in the Investment Banking division of Lehman Brothers, specializing in Global Healthcare. Mr. Belinfanti received his B.A. in Politics from New York University and his J.D. from Harvard University.

**Terence Connors** has been a member of our board of directors since the closing of the Business Combination. Mr. Connors brings to the board 40 years of public accounting experience. Mr. Connors retired in September 2015 from KPMG LLP, where he served as Professional Practice Partner, SEC Reviewing Partner and as a member of KPMG's board of directors (2011-2015), where he chaired the Audit, Finance & Operations Committee. Prior to joining KPMG in 2002, he was a partner with Arthur Andersen LLP. During his career, he served as a senior audit and global lead partner for numerous public companies, including Fortune 500 companies. Mr. Connors currently serves as a board member and audit committee chairman of two public companies: Suburban Propane Partners L.P. and AdaptHealth Corp. Mr. Connors previously served as a trustee of St. Joseph's Preparatory School in Philadelphia and also served as Chairman and President of the Philadelphia Chapter of the National Association of Corporate Directors (NACD). Mr. Connors received his undergraduate degree in Accounting from LaSalle University.

**Brad Coppens** has served on our board of directors since July 2020. Mr. Coppens is a Senior Partner of InTandem Capital Partners and has been identifying, evaluating and executing private equity transactions in the healthcare services sector for 20 years. In addition to AdaptHealth, Mr. Coppens serves on the board of directors at beBright, Healthfuse, HouseWorks, Providence Care, Sequel Ortho, The Phia Group and Vivo Infusion. Before joining InTandem, he was a Senior Managing Director at One Equity Partners. At One Equity Partners, Mr. Coppens has focused principally in the healthcare industry and has worked on numerous investments in both the healthcare and technology-enabled services industries. From 2012 to 2014, Mr. Coppens lived in São Paulo, Brazil and led One Equity Partners' prior investing efforts in the region. Mr. Coppens has served as a member of the boards of directors of AdaptHealth, AMT/RestorixHealth, Ernest Health, OneLink, ResultsCX, Allied, Cless Cosméticos, Portal de Documentos, Prodigy Health Group, Simplura Health Group, Systagenix Wound Management, Unicoba, Wow! Nutrition and X-Rite. Mr. Coppens was also deeply involved in One Equity Partners' investments in ArthroCare and Wright Medical. Prior to One Equity Partners, Mr. Coppens worked in the investment banking division of JPMorgan in the mergers and acquisitions group where he focused on healthcare and various other industries. Mr. Coppens is actively involved in a number of non-profit organizations and previously served as a board member of The TEAK Fellowship. Mr. Coppens received his B.B.A. from the Stephen M. Ross School of Business at the University of Michigan, where he graduated with high distinction.

**Suzanne Foster** has been the Chief Executive Officer of the Company since May 2024. She is a global leader with more than 25 years of experience in the healthcare industry. Ms. Foster also currently serves on the board of Unitil Corp., a public utility holding company. Prior to AdaptHealth, Ms. Foster served as President of Beckman Coulter Life Sciences for Danaher Corporation, a global science and technology innovation company located in Washington, DC, from April 2022 until May 2024. Ms. Foster also served as President of At Home Solutions for Cardinal Health, Dublin, Ohio, a global, integrated healthcare services and products company, from January 2020 until April 2022, as President of Stanley Healthcare, Waltham, Massachusetts, a healthcare technology operating division of Stanley Black & Decker, from April 2018 until January 2020, and as a general manager of Medtronic Advanced Energy ("Medtronic"), a medical device company, from August 2011 until March 2018. Ms. Foster formerly served as Vice President of Global Business Operations at Salient Surgical Technologies, a medical device company later acquired by Medtronic. She was also formerly employed as an attorney at the law firms of Holland & Knight and Wiggin & Nourie, and she served as Vice President of Legal & Compliance for the Elliot Health System. In 2017, Ms. Foster was appointed to the University System of New Hampshire Board of Trustees by New Hampshire Governor Chris Sununu. She also currently serves on the board of Perimeter Medical Imaging AI, Inc., since 2018, and on multiple boards of private medical technology companies. Ms. Foster holds a B.A. in Communication from the University of New Hampshire, an M.Ed in Psychology from Notre Dame College, a J.D. from Suffolk University Law School, and a Master of Public Health in Law and Health Policy from Harvard T.H. Chan School of Public Health.

**Ted Lundberg** has served on our board of directors since February 2021. Mr. Lundberg is a Founding Partner and Managing Member at Peloton Equity, LLC. Peloton Equity is a private equity firm that focuses on investing in growing healthcare companies. He previously worked at Ferrer Freeman & Company and prior to that, Donaldson, Lufkin and Jenrette. Mr. Lundberg currently serves on the boards of Arcadia Solutions, Inc. HPOne, Inc., Grenova, Inc., ClearSky

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

Health, Inc., Aerosafe Global, Inc. and Journey Health & Lifestyle Brands Inc. Mr. Lundberg holds a B.A. degree from Princeton University.

**Kenneth A. Samet** currently serves as the President and CEO of Medstar Health, Inc. and has over 40 years of experience in healthcare administration. He has been CEO of MedStar Health, Inc. since January 2008, after previously serving as President beginning in 2003 and as Chief Operating Officer beginning in 1998. Earlier, from 1990 to 2000, he was President of MedStar Washington Hospital Center, and from the mid-1980s to 1990 he held a series of leadership roles at Medlantic Healthcare Group. His prior public company board service includes Catalyst Health Solutions, Inc. (2006–2012) and Cogentix Medical, Inc. (2016–2018), and he served on the board of Luminex Corporation from 2018 to 2021. He holds a B.S. in business administration from Old Dominion University and an M.H.S.A. from the University of Michigan.

**Susan Weaver, M.D.** has served on our board of directors since February 2018. Dr. Weaver served as President and then Chief Executive Officer of KEPRO, a technology enabled healthcare services company, from July 2018 until the successful sale of the company in December 2022. She previously served as the Chief Executive Officer of C3 HealthcareRX and as the Founder and President of Transformation Health Partners, LLC. Dr. Weaver also served as the Chief Medical Officer for Blue Cross Blue Shield of North Carolina from 2014 to 2015 after serving as the Vice President, Health Delivery Redesign from 2012 to early 2014. Prior to joining Blue Cross Blue Shield of North Carolina, Dr. Weaver served in various leadership roles at WakeMed Health & Hospitals, including Executive Vice President, Medical Affairs. Dr. Weaver also previously served as an Executive Director and Physician and founding member for Alliance Medical Ministry, a 501(c)(3) providing medical care to the working uninsured of Wake County, North Carolina. She holds an M.D. from Duke University School of Medicine and a B.S. in Psychology from Duke University.

**David S. Williams III** has served on our board of directors since July 2020. Mr. Williams is a serial entrepreneur and currently co-founder and CEO of Care3, a digital health equity solution for health plans and providers. Prior to Care3, Mr. Williams was Co-Founder and CEO of InvolveCare (funded by Aetna) and a Founding Executive of PatientsLikeMe (acquired by United Health Group). He has also held corporate positions at Eli Lilly and Company and Deloitte. Mr. Williams also currently serves on the board of directors of Lifespace Communities, Inc., a private senior living company with 14 locations in seven states. Mr. Williams is a Henry Crown Fellow of The Aspen Institute and a member of the Aspen Global Leadership Network. Mr. Williams earned a BS in Economics and Entrepreneurial Management from The Wharton School of the University of Pennsylvania and an MBA in Digital Strategy with a certificate in Corporate Governance from the UCLA Anderson School of Management.

**Dale Wolf** has served on our board of directors since the closing of the Business Combination. Mr. Wolf has served as a member of the board of directors of EHealth, Inc. since 2019. He has also served as a member of the board of directors of Molina Healthcare, Inc. since 2013 and as chairman of the board since 2017. Mr. Wolf served as the President and Chief Executive Officer of Onecall Care Management Inc. from January 2016 to February 2019 and as executive chairman from September 2015 to January 2016. Mr. Wolf served as the President and Chief Executive Officer of DBW Healthcare, Inc. from January 2014 to June 2018. Mr. Wolf served as the executive chairman of Correctional Healthcare Companies, Inc., a national provider of correctional health care solutions, from December 2012 to July 2014. From 2005 to 2009, Mr. Wolf served as Chief Executive Officer of Coventry Health Care, Inc., a diversified national health care company, and served as the Executive Vice President, Chief Financial Officer and Treasurer of Coventry Health Care, Inc. from 1996 to 2005. Mr. Wolf was also a member of the boards of directors of Correctional Healthcare Companies, Inc. from 2012 to 2014, Coventry Healthcare, Inc. from 2005 to 2009 and Catalyst Health Solutions, Inc. from 2003 to 2012. Mr. Wolf graduated from Eastern Nazarene College with a Bachelor of Arts degree in Mathematics, with honors, and from the MIT Sloan School Senior Executive Program. He has also been a fellow in the Society of Actuaries since 1979.

The following is biographical information as of April 28, 2026 for a current director whose term will expire at the conclusion of the 2026 Annual Meeting:

**Diana Nole** has served on our board of directors since October 2024 and has over 18 years of senior leadership experience in the Healthcare AI and Healthcare IT industries. She most recently served as the Executive Vice President and General Manager of the Healthcare division of Nuance Communications, a Microsoft Cloud & AI company that provides AI-driven clinical documentation creation, clinical revenue cycle integrity and diagnostic radiology cloud solutions to the global healthcare industry. In this role, she worked to accelerate recurring revenue growth, successfully completed the divestiture of a declining business segment and developed the leadership team and culture in an effort to create sustainable growth and innovation. She has also served as the CEO of Wolter Kluwers' Healthcare division from September 2015 to May 2020, president of Carestream's Digital Medical Solutions business from August 2007 to August 2015, and vice

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

president of strategy, product management, and marketing for Eastman Kodak's Healthcare Information Technology Solutions business. Ms. Nole has dual degrees in Computer Science and Math from the State University of New York at Potsdam and earned her MBA from the University of Rochester's Simon School.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**PROPOSAL NO. 2 — RATIFICATION OF SELECTION OF INDEPENDENT** 

 **REGISTERED PUBLIC ACCOUNTING FIRM**

The Audit Committee has selected KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 and has further directed that the selection of the independent registered public accounting firm be submitted for ratification by our stockholders at the Annual Meeting. KPMG LLP has advised the Company that it has no direct or indirect financial interest in the Company or any of its subsidiaries and that it has had, during the last three years, no connection with the Company or any of its subsidiaries other than as our independent registered public accounting firm and certain other activities as described below.

Neither our bylaws nor our other organizational documents or applicable law require stockholder ratification of the selection of KPMG LLP as our independent registered public accounting firm. However, the Audit Committee is submitting the selection of KPMG LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such a change would be in our best interests or those of our stockholders.

KPMG LLP will have a representative present at the meeting who will have an opportunity to make a statement if he or she so desires and to respond to appropriate questions from stockholders.

**Independent Registered Public Accounting Firm**

KPMG LLP, which served as our independent registered public accounting firm for the fiscal years ended December 31, 2025 and 2024, provided audit and tax services to us during those fiscal years. The following table presents fees for professional services rendered by our independent registered public accounting firm:

---

| | | |
|:---|:---|:---|
| **Type of Fees** | **Fiscal 2025**  | **Fiscal 2024** |
| Audit Fees | $4625000 | $5124285 |
| Audit-Related Fees |  |  |
| Tax Fees | 858902 | 963541 |
| All Other Fees |  |  |
| Total | $5483902 | $6087826 |

---

***Audit Fees***

This category includes fees associated with our annual audit of our consolidated financial statements and the effectiveness of our internal control over financial reporting and the review of our quarterly reports on Form 10-Q. This category also includes advice on accounting matters that arose during, or as a result of, the audit or the review of our interim financial statements, and the review of our SEC regulatory filings.

***Audit-Related Fees***

There were no audit-related fees billed to us for 2025 or 2024.

***Tax Fees***

This category includes fees for tax compliance of $652,500 and $765,169 for 2025 and 2024, respectively, with the remainder primarily for tax planning and technical advice on mergers and acquisitions.

***All Other Fees***

There were no other fees billed to us for 2025 or 2024.

**Audit Committee Pre-Approval Policies and Procedures**

Our policy is that all audit and non-audit services must be pre-approved by the Audit Committee. The authority to grant pre-approvals of services may be delegated to one or more of the Audit Committee's members, but the decision must be reported to the full Audit Committee at its next scheduled meeting. All of such services and fees were pre-approved during the fiscal year ended December 31, 2025 and 2024.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**Vote Required for Approval**

The approval of the ratification of appointment of KPMG LLP requires the affirmative vote of a majority of the votes cast by the holders of outstanding Common Stock present in person or represented by proxy at the Annual Meeting and entitled to vote on Proposal 2. Failure to vote by proxy or to vote in person at the Annual Meeting or an abstention from voting will have no effect on the outcome of the vote on the ratification of appointment of KPMG LLP.

**OUR BOARD OF DIRECTORS RECOMMENDS THAT OUR STOCKHOLDERS VOTE "FOR" THE APPROVAL OF THE RATIFICATION OF SELECTION OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE YEAR ENDING DECEMBER 31, 2026.** 

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**PROPOSAL NO. 3 — SAY-ON-PAY**

**Background**

Section 14A of the Exchange Act requires us to request stockholder approval, on an advisory basis, of the compensation paid to our named executive officers ("**NEOs**") as disclosed pursuant to the SEC's compensation disclosure rules. This proposal is commonly known as a "say-on-pay" proposal.

As part of our Compensation Committee's efforts to ensure that the interests of our NEOs are aligned with those of our stockholders, our Compensation Committee will consider the results of this "say-on-pay" vote on executive compensation. Our Compensation Committee will consider stockholder feedback when reviewing, designing and implementing our executive compensation program.

The Compensation Discussion and Analysis beginning on page <u>[23](#icb8b7d474fb54376885edd8b3dcbbb72_43)</u> of this proxy statement sets forth detailed information about our executive compensation program. As discussed there, our executive compensation program is designed to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Link pay with performance

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Provide an appropriate mix of fixed and at-risk compensation to attract and retain key talent who thrive in a results-driven environment

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Set competitive pay levels to effectively attract and retain key talent

Consistent with these goals our executive compensation program emphasizes performance-based pay, with 2025 metrics including Net Revenue, Adjusted EBITDA, Free Cash Flow, and relative total shareholder return ("TSR").

**Vote Required for Approval**

You may vote "FOR," "AGAINST" or "ABSTAIN" with respect to the non-binding approval of our fiscal 2025 executive compensation. The affirmative vote of a majority of all votes cast at the Annual Meeting or by proxy is required to approve this non-binding advisory proposal. For purposes of this non-binding advisory vote, any shares not voted (whether by abstention, broker non-vote, or otherwise) will not be counted as a vote cast and will have no impact on the result of the vote, although abstentions will count toward the presence of a quorum.

The vote of the stockholders with respect to this proposal is an advisory vote, and the results will not be binding on our board of directors. However, the board of directors and our Compensation Committee, which is composed entirely of independent directors, will consider the outcome of the vote when making future decisions regarding executive compensation.

As an advisory vote, this proposal is not binding upon the Company. However, our Compensation Committee will use stockholder feedback, both as expressed by your "say-on-pay" vote and as provided directly to us, as an important consideration in making future NEO compensation decisions.

**OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE "FOR" ADOPTION OF THE FOLLOWING RESOLUTION:**

**RESOLVED, THAT THE STOCKHOLDERS OF THE COMPANY APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS FOR FISCAL YEAR 2025, AS DISCLOSED WITHIN THIS PROXY STATEMENT PURSUANT TO THE COMPENSATION DISCLOSURE RULES OF THE EXCHANGE ACT (ITEM 402 OF REGULATION S-K), WHICH DISCLOSURE INCLUDES THE COMPENSATION DISCUSSION AND ANALYSIS, SUMMARY EXECUTIVE COMPENSATION TABLES AND RELATED NARRATIVE INFORMATION CONTAINED IN THIS PROXY STATEMENT.** 

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE**

**Board of Directors and Terms of Office of Officers and Directors**

At the 2024 Annual Meeting, our stockholders voted to approve the elimination of our classified board structure over three years. As of this Annual Meeting the declassification of the Board is complete and all directors will stand for election annually.

Pursuant to the terms of the Deerfield Subscription Agreement, Deerfield was entitled, at the closing of the Business Combination, to designate for nomination by us for election one director to serve on our board of directors. Deerfield designated Dr. Susan Weaver.

Pursuant to the terms of the BlueMountain Board Designee Rights Letter Agreement, the BlueMountain Entities or their permitted transferees holding a majority of the outstanding principal amount under the BM Notes had the right to designate and nominate for election one director to our board of directors. BlueMountain's designee was Dale Wolf.

Pursuant to the terms of the OEP Investment Agreement, for as long as OEP holds beneficial ownership of at least 25% of the shares of capital stock of the Company purchased thereunder, OEP has the right to designate and nominate for election one director to our board of directors. OEP's initial designee was Brad Coppens. OEP's sole current designee is Gregory Belinfanti.

Pursuant to the terms of the AeroCare Merger Agreement, for so long as Peloton Equity AeroCare SPV I, L.P. and SkyKnight Aero Holdings, LLC or an affiliate thereof (the "**AeroCare Sellers**") hold in the aggregate among them at least 35% of the share consideration issued to them under the AeroCare Merger Agreement, on an as-converted basis, the AeroCare Sellers have the right to nominate one director to our board of directors. The AeroCare Sellers' designee is Ted Lundberg.

The Board held five meetings during 2025. No incumbent director attended fewer than 75% of the meetings of the board of directors and no incumbent director attended fewer than 75% of the meetings of the committees of the board of directors on which he or she served (in each case, which were held during the period for which such incumbent director was a director). Nine of our incumbent directors attended the prior year's annual meeting. We do not have a policy mandating director attendance at annual meetings of our stockholders, but we strongly encourage directors to attend.

Officers are appointed by our board of directors and serve at the discretion of our board of directors, rather than for specific terms of office.

**Director Independence**

Our shares of Common Stock are listed on the Nasdaq Capital Market and trade under the symbol "AHCO" and we are subject to Nasdaq listing standards. Nasdaq Listing Rule 5605 requires a majority of a listed company's board of directors to be comprised of independent directors. In addition, the Nasdaq listing standards require that, subject to specified exceptions, each member of a listed company's audit, compensation and corporate compliance and governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act. Under Rule 5605(a)(2), a director will qualify as an "independent director" only if, in the opinion of our board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (1) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (2) be an affiliated person of the listed company or any of its subsidiaries.

Our board of directors has undertaken a review of the composition of our board and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that none of Messrs. Belinfanti, Connors, Coppens, Lundberg, Samet, Williams, and Wolf, and Dr. Weaver, representing eight of our nine director nominees, has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is "independent" as that term is defined under Nasdaq Listing Rule 5605(a)(2).

Our board of directors also determined that Messrs. Connors, Coppens, Lundberg, Samet and Wolf, who comprise our Audit Committee, Messrs. Belinfanti, Coppens, Williams, and Dr. Weaver, who comprise our Compensation Committee,

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

and Messrs. Belinfanti, Connors, Lundberg, and Williams and Dr. Weaver, who comprise our Corporate Compliance and Governance Committee, satisfy the independence standards for such committees established by the Securities and Exchange Commission, or the SEC, and Nasdaq listing standards, as applicable. In making such determination, our board of directors considered the relationships that each such non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining independence, including beneficial ownership of our capital stock.

**Board Leadership Structure and Role in Risk Oversight**

Dale Wolf serves as the Chairman of our Board, and Suzanne Foster serves as our Chief Executive Officer. We generally believe that the most effective leadership structure is to have separate Chair of the Board and Chief Executive Officer positions because this allows the board of directors to benefit from having multiple strong voices bringing separate views and perspectives to meetings. Our Corporate Governance Guidelines provide that the Board may appoint an independent director to serve as "Lead Independent Director" for a one-year term if the individual elected as Chair is not an independent director.

**Committees of the Board of Directors**

The standing committees of our board of directors currently consist of an Audit Committee, a Compensation Committee, and a Corporate Compliance and Governance Committee. Each committee reports to the board of directors as it deems appropriate and as the Board may request. The composition, duties and responsibilities of these committees are set forth below.

***Audit Committee***

Our Audit Committee consists of Terence Connors, who serves as the Chair of the Audit Committee, Brad Coppens, Ted Lundberg, Ken Samet<sup>3</sup> and Dale Wolf. Under Nasdaq listing standards and applicable SEC rules, we are required to have at least three members of the Audit Committee, all of whom must be independent. We have determined that each of Messrs. Connors, Wolf, Lundberg, Samet and Coppens qualifies as independent under Nasdaq listing standards and applicable SEC rules with respect to Audit Committee membership. We have also determined that Mr. Connors qualifies as an "Audit Committee Financial Expert" as defined in applicable SEC rules. During fiscal year 2025, our Audit Committee met five times, including telephonic meetings.

The Audit Committee charter, which is available on our website at https://www.adapthealth.com/investorrelations/governance, details the principal functions of the Audit Committee, including:

&nbsp;&nbsp;&nbsp;&nbsp;• the appointment, compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm and any other independent registered public accounting firm engaged by us; pre-approving all audit and non-audit services to be provided by the independent registered public accounting firm or any other independent registered public accounting firm engaged by us, and establishing pre-approval policies and procedures;

<sup>3</sup> Mr. Samet will join the Audit Committee effective as of the 2026 Annual Meeting if elected.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

&nbsp;&nbsp;&nbsp;&nbsp;• reviewing and discussing with the independent registered public accounting firm all relationships the auditors have with us in order to evaluate their continued independence;

&nbsp;&nbsp;&nbsp;&nbsp;• reviewing and discussing with the General Counsel, Chief Compliance Officer, and/or any other senior-level management representative, as the committee deems necessary, the accuracy of public disclosures with respect to material investigations involving the Company's officers and directors that are required to be disclosed under state and/or federal laws and regulations (if any);

&nbsp;&nbsp;&nbsp;&nbsp;• setting clear hiring policies for employees or former employees of the independent registered public accounting firm;

&nbsp;&nbsp;&nbsp;&nbsp;• setting clear policies for audit partner rotation in compliance with applicable laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;• obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing (i) the independent registered public accounting firm's internal quality control procedures and (ii) any material issues raised by the most recent internal quality control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within, the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues;

&nbsp;&nbsp;&nbsp;&nbsp;• reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction;

&nbsp;&nbsp;&nbsp;&nbsp;• reviewing with management, the independent registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities;

&nbsp;&nbsp;&nbsp;&nbsp;• reviewing and assessing the Company's major financial risk exposures and the manner in which such risks are being monitored and controlled; and

&nbsp;&nbsp;&nbsp;&nbsp;• overseeing the adequacy and effectiveness of the Company's monitoring of and system of internal controls over cybersecurity matters.

***Compensation Committee***

Our Compensation Committee consists of Gregory Belinfanti, Brad Coppens, David Williams and Susan Weaver, and Mr. Coppens serves as Chair of the Compensation Committee. Under the Nasdaq listing standards and applicable SEC rules, we are required to have at least two members of the Compensation Committee, all of whom must be independent. We have determined that each of Messrs. Coppens, Williams and Belinfanti, and Dr. Weaver qualifies as independent under Nasdaq listing standards and applicable SEC rules. Our Compensation Committee held five meetings during 2025. The Compensation Committee charter, which is available on our website at https://www.adapthealth.com/investorrelations/governance, details the principal functions of the Compensation Committee, including:

&nbsp;&nbsp;&nbsp;&nbsp;• reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer's compensation, evaluating our Chief Executive Officer's performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation in executive session at which the Chief Executive Officer is not present;

&nbsp;&nbsp;&nbsp;&nbsp;• reviewing and approving the compensation of all of our other executive officers;

&nbsp;&nbsp;&nbsp;&nbsp;• reviewing our executive compensation policies and plans;

&nbsp;&nbsp;&nbsp;&nbsp;• implementing and administering our equity-based remuneration plans;

&nbsp;&nbsp;&nbsp;&nbsp;• assisting management in complying with our SEC filings;

&nbsp;&nbsp;&nbsp;&nbsp;• approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees;

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

&nbsp;&nbsp;&nbsp;&nbsp;• producing a report on executive compensation to be included in our annual proxy statement; and

&nbsp;&nbsp;&nbsp;&nbsp;• reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.

The Compensation Committee is responsible for determining appropriate compensation levels and arrangements for our executive officers and directors, ensuring that our compensation program is consistent with our compensation philosophy and peer company practices. In making these determinations, the Compensation Committee considers each executive officer's individual performance, the recommendations of our Chief Executive Officer, and additional factors, such as the executive officer's responsibilities, experience level and tenure. In addition, the Compensation Committee continued to engage ClearBridge Compensation Group ("ClearBridge") as its independent compensation advisor in 2025 as described in the Compensation Discussion and Analysis on page <u>[23](#icb8b7d474fb54376885edd8b3dcbbb72_43)</u> of this proxy statement.

In determining the levels and mix of executive and director compensation, our Compensation Committee does not generally rely on formulaic guidelines, but rather maintains a flexible approach to compensation determinations, which allows it to adapt the various elements of compensation to motivate individual executives and achieve our specific strategic and financial goals. The Compensation Committee then approves, with any modifications it deems appropriate, base salaries, target annual incentive bonuses and grants for our executive officers and directors, as applicable.

The charter also provides that the Compensation Committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and is directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the Compensation Committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC. Other than the engagement of ClearBridge described above, the Compensation Committee has not retained a compensation consultant to recommend or assist in determining the amount or form of executive or director compensation.

The Compensation Committee may delegate to any one of its members or any subcommittee it may form, the responsibility and authority for any particular matter, as it deems appropriate from time to time under the circumstances.

***Corporate Compliance and Governance Committee***

Our Corporate Compliance and Governance Committee is responsible for, among other matters: (i) identifying individuals qualified to become members of our board of directors consistent with criteria approved by our Board; (ii) assessing the composition and functioning of the Board and its committees; (iii) developing and maintaining the Company's corporate governance policies and any related matters required by the federal securities laws; (iv) overseeing the Company's environmental, social and corporate governance strategy and initiatives; (v) overseeing the organization of the Board to discharge the Board's duties and responsibilities properly and efficiently; and (vi) periodically assessing and making recommendations to the Board regarding management's implementation of the Compliance Program elements.

Our Corporate Compliance and Governance Committee consists of Gregory Belinfanti, Terence Connors, Ted Lundberg, who serves as Chair of the committee, David Williams and Dr. Susan Weaver. We have determined that each of Messrs. Connors, Williams, Lundberg, Belinfanti and Dr. Weaver qualifies as independent under Nasdaq listing standards and applicable SEC rules. Our Corporate Compliance and Governance Committee met five times in 2025. The written charter for the Corporate Compliance and Governance Committee is available on our website at https://www.adapthealth.com/investorrelations/governance.

Subject to the OEP Investment Agreement and the AeroCare Merger Agreement discussed elsewhere in this proxy statement, which provide certain of our stockholders with rights to designate director nominees, the Corporate Compliance and Governance Committee uses a variety of methods for identifying and evaluating nominees for director. In recommending director nominees to the Board apart from those nominees designated pursuant to the OEP Investment Agreement and the AeroCare Merger Agreement, the committee solicits candidate recommendations from its own members, other directors and management. The committee assesses the appropriate size of the Board and whether any vacancies on the Board are expected due to retirement or otherwise. If vacancies are anticipated, or otherwise arise, and the designation provisions of the OEP Investment Agreement and the AeroCare Merger Agreement do not apply, the committee considers whether to fill those vacancies and, if applicable, considers various potential director candidates. The committee evaluates any such candidates at regular or special meetings of the committee, and such candidates may be considered at any point during the year.

The Corporate Compliance and Governance Committee has not adopted specific, minimum qualifications or specific qualities or skills that must be met by a Corporate Compliance and Governance Committee-recommended

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

nominee. The committee seeks to ensure that the membership of the Board and each committee of the Board satisfies all relevant Nasdaq listing standard requirements and applicable laws and regulations and all requirements of our organizational documents. The nature of the specific qualifications, qualities, experience or skills that the committee may look for in any particular director nominee who is not a designee under the OEP Investment Agreement or the AeroCare Merger Agreement depends on the qualifications, qualities and skills of the rest of the directors at the time of any vacancy on the Board. In addition, on an annual basis, the committee evaluates the composition of the Board by (a) assessing the skills and expertise that are currently represented on the Board as a whole, and in individual directors, as well as the skills and experience that the Board may find valuable in the future and (b) assessing the effectiveness of the efforts to seek a diversity of occupational and personal backgrounds on the Board in order to obtain a range of viewpoints and perspectives and to enhance the diversity of the Board.

The Corporate Compliance and Governance Committee also considers director candidates recommended for nomination by our stockholders during such times as they are seeking proposed nominees to stand for election at the next Annual Meeting. Our stockholders that wish to nominate a director for election to our Board should follow the procedures set forth in our bylaws.

**Code of Ethics and Committee Charters**

We have adopted a Code of Ethics applicable to our directors, officers and employees. Our Code of Ethics, Audit Committee charter, Compensation Committee charter and Corporate Compliance and Governance Committee charter are available free of charge on our corporate website at https://www.adapthealth.com/investorrelations/governance. The information on our website does not constitute part of this proxy statement. In addition, a copy of our Code of Ethics will be provided without charge upon request from us. We intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics on our corporate website at the address above.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**REPORT OF THE AUDIT COMMITTEE**

Our management has primary responsibility for establishing and maintaining effective internal control over financial reporting and preparing our consolidated financial statements and disclosures. KPMG LLP, our independent registered public accounting firm for 2025, was responsible for performing an independent audit of our consolidated financial statements and expressing opinions on the conformity of our consolidated financial statements with generally accepted accounting principles in the United States and on the effectiveness of our internal control over financial reporting. Our Audit Committee oversaw the performance of these responsibilities by KPMG LLP and management, including the processes by which these responsibilities are fulfilled.

Our Audit Committee has reviewed our audited consolidated financial statements for the fiscal year ended December 31, 2025 and discussed them with our management and KPMG LLP.

Our Audit Committee has also received from, and discussed with, KPMG LLP various communications that KPMG LLP is required to provide to our Audit Committee, including the matters required to be discussed by Auditing Standard No. 1301, *Communications with Audit Committees*, as adopted by the Public Company Accounting Oversight Board.

In addition, our Audit Committee has received the written disclosures and a letter from KPMG LLP required by applicable requirements of the Public Company Accounting Oversight Board regarding KPMG LLP's communications with our Audit Committee concerning independence, and has discussed with KPMG LLP their independence.

Based on the review and discussions referred to above, our Audit Committee has recommended to the board of directors that the audited consolidated financial statements be included in the Annual Report on Form 10-K for the year ended December 31, 2025, filed by us with the SEC.

Respectfully submitted,

**The Audit Committee of the Board of Directors**

Terence Connors, Chair

Brad Coppens

Ted Lundberg

Diana Nole

Dale Wolf

*The material in this report is not "soliciting material," shall not be deemed "filed" with the SEC and shall not be incorporated by reference in any filing of AdaptHealth Corp. under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.*

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**EXECUTIVE AND DIRECTOR COMPENSATION**

**Identification of Executive Officers**

The following table sets forth the name, age and position of each of our executive officers as of April 28, 2026:

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position** |
| Suzanne Foster | 56 | Chief Executive Officer |
| Jason Clemens | 48 | Chief Financial Officer |
| Toby Scott Barnhart | 58 | Chief Operating Officer |
| Russell Schuster | 49 | Chief Commercial Officer |
| Albert Prast | 65 | Chief Technology Officer |
| Christine Archbold | 52 | Chief Accounting Officer |
| Richard Rew | 58 | Chief Legal Officer, General Counsel & Secretary |
| Daniel McFadden | 55 | Chief Business Systems Officer |

---

The following is biographical information as of April 28, 2026 for our executive officers other than Ms. Foster, whose biographical information appears above in Proposal 1 — Election of Directors.

**Jason Clemens** joined AdaptHealth in 2020 from MEDNAX, Inc, a national provider of health solutions to hospitals, health systems, and healthcare facilities, where he served as Senior Vice President and Operations Chief Financial Officer. Over a nine-year career at MEDNAX, Mr. Clemens held positions of increasing responsibility in operations management and finance. Prior to joining MEDNAX, Mr. Clemens gained experience with the United States Army, supporting the Republic of Korea Army in Wonju, South Korea. He later served in progressive roles within operations management and finance at Accenture, Lennar, and Ryder. Mr. Clemens holds a B.S. in Industrial Engineering from Lehigh University, and an M.S. in Finance and an M.B.A. from the Indiana University Kelley School of Business. He is also a Chartered Financial Analyst (CFA) and a Certified Six Sigma Blackbelt.

**Toby Scott Barnhart** joined AdaptHealth in 2024 as Chief Operating Officer. Prior to that, from September 2022 until September 2024, Mr. Barnhart served as the Chief Operating Officer of Qurate Retail Group ("Qurate"), a world leader in video commerce across linear TV, e-commerce sites, digital streaming and social platforms. Prior to Qurate, Mr. Barnhart served as president of Global Medical Products & Supply Chain at Cardinal Health from July 2018 to December 2021 and as President, Global Supply Chain & Group Purchasing Organizations at Aramark from April of 2014 to July 2018. Mr. Barnhart also held senior supply chain positions at Conagra Brands and Diageo from September 2002 to April 2014. Early in his career, Mr. Barnhart advised other global companies as a consultant at PwC and E&Y. Mr. Barnhart serves on the Board of Directors of Common Threads. Scott earned his bachelor's degree from Purdue University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Barnhart has significant international business leadership experience in global supply chain, manufacturing, procurement, customer service and product portfolio management at multiple Fortune 500 brands and similarly sized corporations.

**Russell Schuster** joined AdaptHealth in 2024 from Cardinal Health, where he most recently served as the President for Cardinal Health Canada since November 2020. During his time as President, the business experienced significant organic revenue growth and margin expansion through the implementation and execution of a multi-year strategic plan, refocused commercial strategy and implementation of operating efficiency programs. Previously, he held the role of Senior Vice President and led the Global Strategy and Business Development efforts for the Medical Segment at Cardinal Health. Mr. Schuster joined Cardinal Health in 2017 as a Vice President, Corporate Development with responsibility for identification and execution of M&A, Partnerships and Joint Ventures across the enterprise. Mr. Schuster has nearly 25 years' experience in corporate finance, strategy and M&A work and, immediately prior to joining Cardinal Health, he led corporate development efforts for Republic Services in Chicago, IL. Earlier in his career, Mr. Schuster was a Senior Vice President in investment banking advisory with Barclays (Lehman Brothers). Prior to that, he was with the Transaction Advisory and Corporate Audit groups at Ernst & Young LLP. Mr. Schuster received his M.B.A. from Northwestern University Kellogg School of Management's accelerated 1-Year program and his bachelor's in Accounting/Business Law from Miami University (OH). He is a CPA and previously served on the Board of Directors for MedTech Canada and naviHealth, Inc. until its acquisition by Optum in 2020.

**Albert Prast** joined AdaptHealth in February 2021. Mr. Prast has worked in management roles in the information technology industry for 25 years, specifically as the executive leader of technology vision, strategy, and execution for a

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

number of healthcare companies. Currently, Mr. Prast serves as the Chief Technology Officer of AdaptHealth. Previously, Mr. Prast served as the chief information and chief technology officer for AeroCare. At AeroCare, Mr. Prast focused on implementing technology solutions to enhance efficiency and create a competitive advantage in an industry that has historically relied on paper-based operations. Mr. Prast is also an active investor and advisor to healthcare technology companies and serves on a number of boards, including DataLink Software, ClinOne, RxREvu, ClearSense, and Rancho Family Medical Group.

**Christine Archbold** joined AdaptHealth in 2022 as AdaptHealth's Senior Vice President of Corporate Accounting. Ms. Archbold was promoted to Chief Accounting Officer and principal accounting officer in March 2023. Ms. Archbold previously has held a variety of senior financial management positions, including Chief Accounting Officer and Global Corporate Controller at Clarivate from 2017 to 2022, Global Controller (from 2014 to 2017) and Director of Financial Reporting (from 2011 to 2014) at Houghton International. In these roles, Ms. Archbold had overall responsibility for the controllership, financial reporting, and systems of internal controls. Prior to joining Houghton International in 2011, Ms. Archbold was an auditor with the accounting firm of Ernst & Young LLP. Ms. Archbold holds a B.S. in Accounting from Saint Joseph's University.

**Richard Rew** has been the Chief Legal Officer and General Counsel of the Company since January 2025. Mr. Rew joined the Company from Human Power of N Company (HumanN), a leading dietary supplement company where he is currently a Board Advisor, and previously served as Chief Legal Officer and General Counsel from August 2024 to December 31, 2024. Mr. Rew served as Chief Legal Officer of Tabula Rasa Healthcare, a specialty pharmacy, from April 2023 until its sale to CarePathRx in November 2023; Senior Vice President & General Counsel of IsoPlexis, a leader in functional single-cell proteomics, from October 2021 until its sale to Berkely Lights, Inc. in March 2023; and as Senior Vice President & General Counsel of Luminex Corporation, a leading biological testing company, from 2015 until its sale to DiaSorin in July 2021. Mr. Rew also served as Chief Compliance Officer of Luminex from February 2021 until the sale of the Company to DiaSorin. Mr. Rew was previously in the legal department at ArthroCare Corporation, a medical device company, serving as Vice President, Legal Affairs, from 2006 to 2009 and then as Senior Vice President & General Counsel, from 2009 until its sale to Smith & Nephew in 2014. Mr. Rew resides in Austin, Texas and is a member of the State Bar of Texas and serves on the Board of Directors of the Austin Bar Foundation. He received a B.A. From the Plan II Honors Program at the University of Texas at Austin and a J.D. from the University of Oklahoma College of Law.

**Daniel McFadden** joined AdaptHealth in March of 2025 as Chief Business Systems Officer. He has more than 30 years of international business experience in various general management, continuous improvement, operations, supply chain, and engineering leadership roles across several industries. Prior to AdaptHealth, Mr. McFadden was Senior Vice President Business Systems at Regal Rexnord, a global industrial automation and powertrain company. Mr. McFadden also served as Vice President Operations, Supply Chain, and Danaher Business System, as well as interim President at Beckman Coulter Life Sciences for Danaher Corporation. Additionally, he served as Vice President Operations, Supply Chain, and Carlisle Business System at Carlisle Companies as well as Vice President Manufacturing, Distribution, and Logistics at Videojet, a Danaher operating company. Mr. McFadden also spent a significant portion of his early career at the Timken Company with increasing responsibility in research & development, operations, supply chain, and general management. Mr. McFadden holds a B.S. in Mechanical Engineering from The Ohio State University and Master of Engineering Management from Case Western Reserve University.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**STOCK PERFORMANCE GRAPH**

The following graph compares the yearly percentage change in cumulative total stockholder return of our common stock during the period from 2020 to 2025 with (i) the cumulative total return of the S&P 600 index and (ii) the cumulative total return of the S&P Healthcare Services Select Industry Index. The comparison assumes $100 was invested on December 31, 2020 in our common stock and in each of the foregoing indices and the reinvestment of dividends through December 31, 2025 (last trading day of the year). The stock price performance on the following graph is not necessarily indicative of future stock price performance.

This graph shall not be deemed incorporated by reference by any general statement incorporating by reference this Proxy into any filing under the Securities Act or under the Exchange Act, except to the extent that AdaptHealth specifically incorporates this information by reference, and shall not otherwise be deemed filed under the Securities Act or the Exchange Act.

**Indexed Returns**

![1044](ahco-20260428_g1.jpg)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Company/Index** | **12/31/2020** | **12/31/2021** | **12/30/2022** | **12/29/2023** | **12/31/2024** | **12/31/2025** |
| **AdaptHealth Corp.** | $100.00 | $65.12 | $51.17 | $19.41 | $25.35 | $26.52 |
| **S&P Health Care Services Select Industry Index** | $100.00 | $109.45 | $87.48 | $91.50 | $92.81 | $109.97 |
| **S&P 600 Index** | $100.00 | $125.27 | $103.45 | $117.81 | $125.85 | $131.18 |

---

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**COMPENSATION DISCUSSION & ANALYSIS**

This Compensation Discussion & Analysis section of our Proxy Statement provides a detailed description of our executive compensation programs, decisions, and associated governance for our Named Executive Officers ("NEOs") in 2025. In this section of our Proxy Statement, "Committee" is a reference to the Compensation Committee.

**Named Executive Officers**

Title as of December 31, 2025

**Suzanne Foster**

Chief Executive Officer and Director

**Jason Clemens**

Chief Financial Officer

**Toby Scott Barnhart**

Chief Operating Officer

**Russell Schuster**

Chief Commercial Officer

**Albert Prast**

Chief Technology Officer

_____________________

**<u>EXECUTIVE SUMMARY</u>**

**Year in Review and Alignment of Company Performance with Pay**

In 2025, the Company made significant strides toward building a stronger operational and financial foundation. We transformed our operating model to position the Company for sustained growth. In addition, we closed the largest capitated contract in the industry's history, and strengthened our balance sheet by paying down debt while generating cash flow that exceeded expectations. In the fourth quarter, we continued that momentum with strong patient growth across our portfolio, setting new census records in our Sleep Health, Respiratory Health, and Wellness at Home segments. Our scale and impact remain unmatched in the market, with nearly 10,900 employees servicing approximately 4.3 million patients across the United States. Our performance achievements for 2025 include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net Revenue of $3.24 billion, which represented a decrease of 0.5% over 2024. Net Revenue for 2025 was impacted by the disposition of certain incontinence and infusion businesses during 2025, and to a lesser extent, the disposition of certain custom rehab technology assets during 2024, which combined reduced net revenue by $92.4 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $616.7 million, which represented a decrease of 10.5% over 2024. Adjusted EBITDA is defined as EBITDA plus equity-based compensation expense, change in fair value of the warrant liability, goodwill impairment, loss on extinguishment of debt, litigation settlement expense related to securities litigation, gain on sale of businesses, and other non-recurring items of expense or income. Adjusted EBITDA for 2025 was impacted by a legal settlement expense of $14.5 million and over $10 million of strategic investments to accelerate onboarding of a new capitated contract; the underlying earnings power of the business remains intact.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash Flow from Operations was $601.8 million in 2025, an increase from $541.8 million in 2024, reflecting improved operational efficiency. Free Cash Flow was $219.4 million in 2025, a decrease from $235.8 million in 2024, primarily from an increase in, and timing of, purchases of patient medical equipment for operating requirements. Free Cash Flow is defined as net cash provided by operating activities less cash paid for purchase of equipment and other fixed assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• For additional information on the Company's financial results, see our Annual Report on the Form 10-K for the year ended December 31, 2025.

These achievements were reflected in executive pay outcomes for 2025, aligning with our focus on paying for performance:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Annual cash bonuses were based on our achievement of Net Revenue (40%), Adjusted EBITDA (30%) and Free Cash Flow (30%). Our 2025 Net Revenue results fell between the threshold and target goals, Adjusted EBITDA

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

results fell between the threshold and target goals and Free Cash Flow results were above the maximum goal, resulting in an overall payout of approximately 116.22% of the target for each of our NEOs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In 2025, we granted performance-vested restricted stock units ("PSUs") that will vest based on the Company's total shareholder return (TSR) relative to its defined peers (Relative TSR) for the performance period from February 1, 2025 through January 31, 2028 (or, a change in control, if earlier), as further described in the "Grant of Plan-Based Awards" table.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In recent years, compensation outcomes for our NEOs have demonstrated the Company's pay-for-performance philosophy. A substantial portion of NEO compensation is at-risk (87% for our CEO and 79% on average for our other NEOs). In addition, 50% of our long-term incentives are granted in PSUs tied to relative TSR. The PSUs granted in both 2022 and 2023 were forfeited due to TSR performance below the threshold level relative to the compensation peer group. The 2025 annual incentive paid out above target, recognizing strong financial performance against our rigorous targets. Taken together, these outcomes align realized pay with Company performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In February 2025, the Compensation Committee determined that the PSUs granted in 2022 performed under the threshold performance level and, therefore, paid out at 0%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In February 2026, the Compensation Committee determined that the PSUs granted in 2023 performed under the threshold performance level and, therefore, paid out at 0%.

***Executive Hires***

On November 5, 2024, the Company entered into an employment agreement with Mr. Schuster that governs the terms of his employment as the Chief Commercial Officer of the Company, effective January 2, 2025. The terms of Mr. Schuster's employment agreement are described further in the section labeled "Narrative to Summary Compensation Table — Executive Employment Agreements," and his severance entitlements are described further in the section labeled "Potential Payments Upon Termination or Change in Control."

**Compensation at a Glance**

Our 2025 program was consistent with our past practices and continues to emphasize at-risk, results-driven pay with performance measures focused on key measures of our success in growing profitably and building sustainable value for our stockholders. The high support that our 2025 say-on-pay proposal received, with 94.3% of shares voted cast in favor, was a strong indication that our stockholders are supportive of our approach to executive compensation.

The 2025 target direct compensation mix for our current CEO (Ms. Foster) and other NEOs is illustrated below. The majority (87%) of Ms. Foster's target direct compensation is at-risk variable pay, with 72% consisting of equity incentive awards. For all other NEOs in 2025, at-risk variable pay represents an average of 79% of the target compensation mix, with an average of 58% consisting of equity incentive awards. Further, our target direct compensation mix is substantially performance-based with 50% of our NEOs' target direct compensation being tied to the achievement of preset and rigorous performance goals. The key design features are consistent across all NEOs.

![1767](ahco-20260428_g2.jpg)

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

---

| | |
|:---|:---|
| **Annual Incentive**<br>• 100% payable in cash<br>• 100% tied to financial performance outcomes<br>• Earned based on a combination of Net Revenue, Adjusted EBITDA and Free Cash Flow | **Annual Long-Term Incentives**<br>• Granted an equal mix of PSUs and RSUs<br>• PSUs vest subject to continued employment and three-year cumulative Relative TSR performance<br>• RSUs vest subject to continued employment in three equal annual installments over a three-year period |

---

**<u>COMPENSATION DESIGN</u>**

**Compensation Philosophy and Alignment with Strategic Priorities**

The Company is a national leader in providing patient-centered, healthcare-at-home solutions, including home medical equipment, medical supplies, and related services. To be successful in a competitive marketplace, we need to attract and retain talented employees who are aligned to our mission, vision and values, as well as effective leaders in the fast-paced and high-growth environment in which we operate. The Company's compensation philosophy is to have a program that fully supports the Company's attraction, retention, and stockholder alignment objectives, with an appropriate balance between achieving short-term results and creating long-term sustainable value for stockholders that reinforces and strengthens the linkage between pay and performance.

---

| | |
|:---|:---|
| **Principle** | **How we achieve this** |
| Link pay with performance | ✓Deliver the majority of an NEO's pay in the form of at-risk, variable compensation<br>✓Provide incentive opportunities that can be earned based on robust, simple, transparent, and holistic measures of enterprise-wide performance (currently Net Revenue, Adjusted EBITDA, Free Cash Flow, and Relative TSR)  |
| Provide an appropriate mix of fixed and at-risk compensation to attract and retain key talent who thrive in a results-driven environment<sup>(1)</sup> | ✓Deliver the majority of pay as at-risk and results-driven,<sup>(2)</sup> accounting for an average of 82% for our NEOs <br>✓Deliver at least 50% of each NEO's compensation in performance-based pay, defined as annual bonus and PSUs<br>✓Use a combination of PSUs and RSUs to balance performance-based pay and retention objectives, while collectively aligning with stockholders' interests  |
| Set competitive pay levels to effectively attract and retain key talent | ✓Use an appropriate peer group to provide external context that informs pay decisions <br>✓Reference the market 50th percentile when setting total direct compensation opportunities (the sum of base salary, target bonus and annual equity awards), with positioning against market informed by a range of factors consistent with the Company's compensation philosophy<sup>(3)</sup> |

---

_____________________

(1)Pay mix and equity mix percentages based on target compensation packages effective in 2025.

(2)"Results-driven" pay is considered as performance-based and/or equity-based compensation, the value of which moves in accordance with our stock price performance.

(3)The range of factors that the Committee might consider is detailed in the "Use of Market Data" section.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

To ensure our executive compensation program appropriately balances pay-for-performance objectives, the Committee has elected to align incentive compensation with the following key metrics:

---

| | |
|:---|:---|
| **Performance metric** | **How this aligns with our strategic priorities** |
| Net Revenue<sup>(1)</sup> | ✓Measures our ability to attract new customers and grow organically <br>✓Incentivizes top-line growth that translates to bottom-line value creation for our stockholders  |
| Adjusted EBITDA<sup>(2)</sup> | ✓Measures our ability to grow profitability <br>✓Incentivizes top-line growth, prudent investment and cost management that translates to bottom-line value creation for our stockholders  |
| Free Cash Flow<sup>(2)</sup> | ✓Measures our ability to manage cash from operations after covering purchases of equipment and other fixed assets <br>✓Incentivizes prudent capital allocation and cash management that translates to value creation for our stockholders and our ability to manage debt obligations  |
| Relative TSR | ✓Aligns with stockholders' interests <br>✓Assesses holistic company performance across all strategic priorities through the eyes of stockholders <br>✓Neutralizes impact of macroeconomic events and therefore measures our ability to create superior long-term value relative to peers |

---

_____________________

(1)In 2025, we added Net Revenue and removed Compliance as performance metrics to calculate annual bonuses in order to ensure that annual incentives are directly aligned with key financial performance outcomes (rather than with individual and/or non-financial metrics as used in prior years).

(2)Adjusted EBITDA and Free Cash Flow are non-GAAP financial measures. See below for a reconciliation showing how these metrics are calculated from our 2025 consolidated audited financial statements.

The Company defines EBITDA as net income (loss) attributable to AdaptHealth Corp., plus net income (loss) attributable to noncontrolling interests, interest expense, net, income tax expense (benefit), and depreciation and amortization, including patient equipment depreciation.

The Company defines Adjusted EBITDA as EBITDA (as defined above) plus equity-based compensation expense, change in fair value of the warrant liability, goodwill impairment, loss on extinguishment of debt, litigation settlement expense related to securities litigation, gain on sale of businesses, and other non-recurring items of expense or income.

The following unaudited table presents the reconciliation of net loss attributable to AdaptHealth Corp., to EBITDA and Adjusted EBITDA for the year ended December 31, 2025 (in thousands):

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

---

| | |
|:---|:---|
| Net loss attributable to AdaptHealth Corp. | $(70794) |
| Income attributable to noncontrolling interest | 4756 |
| Interest expense, net | 105753 |
| Income tax expense | 50884 |
| Depreciation and amortization, including patient equipment depreciation | 381927 |
| **EBITDA** | $**472526** |
| Equity-based compensation expense | 21876 |
| Goodwill impairment | 127995 |
| Litigation settlement expense<sup>(1)</sup> | 1000 |
| Gain on sale of businesses | (32602) |
| Other non-recurring expenses, net | 25886 |
| **Adjusted EBITDA** | $**616681** |
| Adjustment<sup>(2)</sup> | 14500 |
| **Adjusted EBITDA utilized for Annual Incentive** | $**631181** |

---

_____________________

(1)The expense represents the estimated amount expected to be funded by the Company relating to a previously disclosed securities settlement.

(2)Represents a litigation settlement expense that was approved by the Compensation Committee as an adjustment for purposes of determining Adjusted EBITDA for payment of the 2025 annual incentive for the Company's NEOs. In making this determination, the Committee considered that the settlement resolved ongoing litigation on favorable terms that was not contemplated in the Company's original budget. The Committee determined that applying the adjustment better aligned pay with Company performance in 2025.

Free Cash Flow is defined as net cash provided by operating activities less cash paid for purchases of equipment and other fixed assets.

The following unaudited table reconciles net cash provided by operating activities to free cash flow for the year ended December 31, 2025 (in thousands):

---

| | |
|:---|:---|
| Net cash provided by operating activities | $601771 |
| Purchases of equipment and other fixed assets | (382388) |
| **Free cash flow** | $**219383** |

---

**Compensation Policies and Practices**

In furtherance of good governance, there are a number of policies and practices applicable to NEOs that we embrace.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

---

| | |
|:---|:---|
| **Practices we follow** | **Practices we avoid** |
| ✓Align pay outcomes with individual and company performance <br>✓Deliver the majority of executive compensation in at-risk pay <br>✓Reference 50th percentile of an appropriately sized Peer Group when making compensation decisions <br>✓Double-trigger vesting on a change in control <br>✓Operate robust share ownership guidelines and share retention requirements <br>✓Maintain a compensation recoupment policy compliant with Nasdaq exchange requirements <br>✓Engage an independent compensation consultant  | 🗶No excise tax gross-ups<br>🗶No discounting or repricing of equity awards <br>🗶No excessive perquisites or benefits <br>🗶No dividends or dividend equivalents are paid on unearned PSUs or RSUs<br>🗶No single-trigger vesting on a change in control |

---

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**<u>COMPENSATION GOVERNANCE</u>**

**Role of the Committee**

The Committee, chaired by Brad Coppens, consists of four directors who are independent under Nasdaq listing standards and applicable SEC rules. The Committee is responsible for determining appropriate compensation levels and arrangements for our executive officers and directors, ensuring that our compensation program is consistent with our compensation philosophy and peer company practices. In making these determinations, the Committee considers each executive officer's individual performance, the recommendations of our Chief Executive Officer (CEO) as applicable, and additional factors, such as the executive officer's responsibilities, experience level and tenure.

The core duties of the Committee include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reviewing and approving annually the Company's compensation philosophy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reviewing and approving annually the compensation of our CEO and other executive officers, in particular the applicable corporate goals and objectives, evaluating performance in light of such goals and objectives, and determining the resulting compensation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reviewing our executive compensation policies and plans;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Implementing and administering our equity-based compensation plans;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Assisting management in complying with our SEC filings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Producing the compensation discussion and analysis on executive compensation to be included in our annual proxy statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reviewing, evaluating, and recommending changes, if appropriate, to the compensation for our directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reviewing the Company's compensation policies and practices to determine if they encourage excessive risk taking that is likely to have a material effect on the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reviewing and recommending/approving changes, if appropriate, to the Committee charter; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Overseeing the Company's Policy for Recovery of Erroneously Awarded Compensation and determining any actions in accordance with the policy.

Our CEO and other relevant members of the management team were invited to attend meetings, as applicable, although were not present when matters regarding their own compensation were discussed. The Committee considers the CEO's input as it relates to the compensation for other executive officers. The full Committee Charter can be found on the Investor Relations page of our website.

**Stockholder Engagement**

We are pleased that 94.3% of votes were cast in favor of our say-on-pay resolution at our 2025 Annual Meeting of Stockholders. This annual vote will provide the Committee regular insight into the views of our aggregate stockholder base, complementing feedback received during targeted outreach and informing future discussions on executive compensation program design.

**Use of Consultants and Advisors**

The Committee has the authority in its charter to retain or obtain the advice of a compensation consultant and other outside advisors. During 2025, the Committee retained ClearBridge as its independent consultant. The Committee assessed ClearBridge's independence in accordance with SEC requirements and concluded that it continued to meet the criteria for independence.

ClearBridge advised and supported the Committee on various matters including, but not limited to, assistance with compensation packages for our current Chief Commercial Officer and Chief Business Systems Officer, executive and non-employee director compensation (including the adoption of our non-employee director compensation deferral program as described in more detail below), an annual review of the compensation peer group, incentive design, completion of a compensation risk assessment, assistance with CD&A and pay versus performance drafting, and regular updates to the

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

Committee on market trends, changing practices, and legislation pertaining to compensation. ClearBridge reports directly to the Committee, attends meetings at the Committee's direction, and with its permission, works with management to gain input and insight on compensation practices and compensation arrangements for certain individual employees.

**Use of Market Data**

The Committee conducts an annual review of the compensation peer group with ClearBridge, which is subsequently used to inform various decisions related to executive compensation.

---

| | |
|:---|:---|
| **How Peer Group companies were selected** | **How the Peer Group is used** |
| • US-listed companies in the healthcare services industry, focused on those providing at-home healthcare equipment, services, and medical supplies <br>• Comparable size based on revenue (~1/3x – 3x range relative to the Company) and market capitalization (~1/5x – 5x relative to the Company) <br>• Competitors for talent <br>• Broader factors such as enterprise value, EBITDA, stock price performance, headcount, and peer-of-peer analysis, were also considered in approving the final Peer Group, but were not primary selection criteria  | • Inform decisions on base salaries, target incentive opportunities and the total target direct compensation opportunity <br>• Determine the level of payout in respect of the Relative TSR performance condition <br>• Provide perspective on compensation policies and practices observed in relevant companies such as employment agreement terms, equity vehicles, equity mix, incentive metrics and stock ownership guidelines |

---

During 2025, the compensation peer group was reviewed to inform 2026 compensation decisions. ModivCare Inc. was removed from the group as the company was delisted from the Nasdaq, and Patterson Companies, Inc. was removed from the group due to transaction activity. The companies that were added to the group are listed in the table below.

---

| | | | |
|:---|:---|:---|:---|
| | **2026 Peer Group**<sup>(1)</sup> | **2026 Peer Group**<sup>(1)</sup> | **2026 Peer Group**<sup>(1)</sup> |
| **Former Peers (2025 only)**  | **Consistent Peers (2025 and 2026)**  | **Consistent Peers (2025 and 2026)**  | **New Peers (2026 only)**  |
| • ModivCare Inc.<br>• Patterson Companies, Inc. | • Addus HomeCare Corporation<br>• Alignment Healthcare, Inc.<br>• AMN Healthcare Services, Inc.<br>• Chemed Corporation<br>• DENTSPLY SIRONA Inc.<br>• Embecta Corp.<br>• Encompass Health Corporation | • The Ensign Group, Inc. <br>• Option Care Health, Inc.<br>• Accendra Health, Inc.<sup>(2)</sup><br>• Pediatrix Medical Group, Inc.<br>• RadNet, Inc.<br>• Select Medical Holdings Corporation  | • Ardent Health, Inc.<br>• Aveanna Healthcare Holdings, Inc.<br>• BrightSpring Health Services, Inc.<br>• Brookdale Senior Living Inc.<br>• Enhabit, Inc.<br>• Surgery Partners, Inc. |

---

(1)Established in 2025 to inform 2026 compensation decisions and to be used as the peer group for the relative TSR conditions applicable to 2026 PSU awards.

(2)Owens & Minor, Inc. rebranded to Accendra Health, Inc. in December 2025.

When insufficient data is available for the Peer Group, the independent consultant provides the Committee with survey data for relevant companies as an alternative and relevant point of reference.

As noted above, one of the primary uses of market data is to inform decisions that the Committee makes as it relates to executive officer compensation levels. In setting individual target direct compensation opportunities, the Committee references the 50th percentile market data for relevant roles in the Peer Group. However, the positioning of an individual's target compensation relative to market will vary, taking account of a range of factors including: role scope and responsibilities; criticality; performance and potential; internal equity; and company performance.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**Compensation and Risk**

The Committee has determined that the Company's compensation policies and practices do not encourage excessive risk taking that is reasonably likely to have a material adverse effect on the Company. The Company maintains several policies that mitigate potential risks related to compensation, which are summarized below.

***Stock Ownership Guidelines***

Our executive officers and non-employee directors are subject to stock ownership guidelines to further align their interests with those of our stockholders. The key features of the guidelines applicable to executive officers and non-employee directors are summarized below.

---

| | |
|:---|:---|
| **Required Ownership** | • CEO: 6x base salary <br>• Other NEOs: 3x base salary <br>• Non-employee directors: 5x annual cash retainer |
| **Period to Comply** | • Five years from becoming a covered person under the policy  |
| **Qualifying Equity Interests** | • Stock owned by the officer, or in which the officer has an interest (e.g., shares that are jointly held with their spouse, or shares held in a trust in which the officer or a family member has an interest) <br>• Unvested time-based restricted stock or RSUs<br>• Note: Directors appointed by an entity will be considered in compliance with the guideline as long as the entity that appointed them maintains ownership above the required level for that individual |
| **Retention Requirement** | • Retention of at least 50% of any after-tax shares acquired upon vesting or settlement of any company-issued equity awards, if the applicable guideline is not met within five years |

---

All of our executive officers and non-employee directors covered by the policy are either currently compliant with the policy or expected to be compliant within the required timeframe.

***Compensation Recovery Policy***

The Committee adopted the Policy for Recovery of Erroneously Awarded Compensation, effective October 2, 2023, in accordance with federal securities laws, SEC rules, and Nasdaq listing rules. This policy provides that, in the event of an accounting restatement, covered executives must repay or return the amount of compensation that is granted, earned, or vested based wholly or in part on a financial reporting measure that exceeds the amount that otherwise would have been received had it been determined based on the restated financial statements. No action was required under the policy during 2025.

***Insider Trading Policy***

Our Insider Trading Policy prohibits those covered by the policy, which includes all of our executive officers and directors, from engaging in short-term trading, short sales, options trading, trading on margin, pledging or hedging transactions. We provide training and distribute periodic reminders to our team members regarding this policy. Any exemption from this requires advance approval from the General Counsel. No exemptions have previously been granted to any executive officer.

**<u>2025 COMPENSATION DECISIONS AND OUTCOMES</u>**

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

***Base Salary***

Base salary is fixed cash compensation provided to our NEOs to reflect their day-to-day responsibilities taking into account, among other things, role scope and performance. As part of the Committee's annual review process and to recognize certain of our NEOs' performance and better support long-term retention, the Committee approved increases to base salary for certain of our NEOs, including for Ms. Foster (from the rate of $900,000 to $1,000,000, effective January 1, 2025) and for Mr. Clemens (from the rate of $650,000 to $670,000, effective January 1, 2025). Provided below are the 2025 annual base salaries for our NEOs.

---

| | |
|:---|:---|
| **Executive** | **2025 Base Salary** |
| Suzanne Foster | $1000000 |
| Jason Clemens | $670000 |
| Toby Scott Barnhart | $600000 |
| Russell Schuster | $450000 |
| Albert Prast | $450000 |

---

***Annual Incentives***

The annual incentive plan enables the Committee to incentivize and reward NEOs for the achievement of performance outcomes that drive the Company's overall results. For 2025, in connection with the evolution of the Company's leadership team and strategic priorities, the Committee amended the annual incentive plan to be 100% based on financial performance metrics (vs. use of a combination of financial, individual, and non-financial metrics as used in prior years). This change reflects the Company's focus on fostering a "OneAdapt" culture and further aligning executive compensation with key financial objectives and drivers of long-term shareholder value creation.

In the first quarter of 2025, the Committee approved the structure of the 2025 annual incentive program for our NEOs. The selected annual incentive metrics of Net Revenue, Adjusted EBITDA, and Free Cash Flow align management with the Company's core priorities of driving sustainable top line growth, improving profitability, and generating cash flow to support balance sheet strength and debt reduction. Given the importance of profitability and cash flow generation, the Company continued to base the annual incentive plan on Adjusted EBITDA and Free Cash Flow and, to further align incentives with top line growth, added Net Revenue as a performance metric for 2025. By weighting the program entirely on financial performance, the Committee reinforces a unified and results oriented approach to executing the Company's strategy.

This design included the following metrics:

---

| | |
|:---|:---|
| **Metric and Associated Weighting** | **All NEOs** |
| FY2025 Net Revenue | 40% |
| FY2025 Adjusted EBITDA | 30% |
| FY2025 Free Cash Flow | 30% |

---

Original performance goals were established with target levels aligned with the Board-approved 2025 budget for Adjusted EBITDA and Free Cash Flow. For Net Revenue, the target was based on an implied year-over-year growth of 2%. Performance ranges around target were defined as follows: for Adjusted EBITDA, threshold and maximum performance levels were set at 90% and 110% of target, respectively; for Free Cash Flow, threshold and maximum were set at 87.5% and 112.5% of target, respectively; and for Net Revenue, threshold performance was set to approximate prior year actual while maximum performance was set at an implied 4% year-over-year growth. Payout opportunities for the financial metrics ranged from 50% of target for threshold performance to 200% of target for maximum performance (with no payout for performance below threshold).

In the first quarter of 2026, the Committee completed its assessment of company performance with reference to goals established in the first quarter of 2025, which were adjusted as a result of disposition activity during 2025 as approved by the Committee. In applying these adjustments, the full impact was reflected in each metric's target, with threshold and maximum levels adjusted proportionately to maintain their positioning relative to the target goal (e.g., for Net Revenue, the adjusted threshold remained at 98% of target and the adjusted maximum at 102% of target). Provided below is a reconciliation of the original goals to the final approved Net Revenue, Adjusted EBITDA and Free Cash Flow goals for 2025.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Below Threshold** | **Threshold** | **Target** | **Maximum** | **Actual** | **Payout** |
| Net Revenue - Original | < $3,261.0M | $3,261.0M | $3,326.2M | $3,391.4M |  |  |
| Adjustments for Dispositions | (77.2)M | (77.2)M | (77.4)M | (77.6)M |  |  |
| Net Revenue - Approved | < $3,183.8M | $3,183.8M | $3,248.8M | $3,313.8M | $3,244.9M | 96.98% |
| Adjusted EBITDA - Original | < $632.2M | $632.2M | $702.4M | $772.7M |  |  |
| Adjustments for Dispositions | (12.2)M | (12.2)M | (13.5)M | (14.9)M |  |  |
| Adjusted EBITDA - Approved | < $620.0M | $620.0M | $688.9M | $757.8M | $631.2M | 58.11% |
| Free Cash Flow - Original | < $183.8M | $183.8M | $210.0M | $236.3M |  |  |
| Adjustments for Dispositions | (20.9)M | (20.9)M | (23.9)M | (26.9)M |  |  |
| Free Cash Flow - Approved | < $162.9M | $162.9M | $186.1M | $209.4M | $219.4M | 200.00% |
| Payout (% of target)<sup>(1)</sup> | 0% | 50% | 100% | 200% |  |  |

---

_____________________

(1)For performance between goals, straight-line interpolation was applied.

Based on 2025 actual results and the corresponding weighting for each metric, the payout percentage was approximately 116.22% of target for all NEOs.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Executive**<sup>(1)</sup>  | **Target Bonus <br> (% of salary)** | **Target Bonus** | **Company <br> Performance <br> Achievement** | **2025 Actual <br> Bonus** |
| Suzanne Foster | 120% | $1200000 | 116.22% | $1394694 |
| Jason Clemens | 100% | $670000 | 116.22% | $778704 |
| Toby Scott Barnhart | 100% | $600000 | 116.22% | $697347 |
| Russell Schuster | 100% | $450000 | 116.22% | $523010 |
| Albert Prast | 100% | $450000 | 116.22% | $523010 |

---

***Long-Term Incentives***

During 2025, annual equity awards to our NEOs were made in an equal combination of PSUs and RSUs, consistent with our historical approach. The number of shares is determined by dividing the target grant value by a 20-trading day volume weighted average price of the Company's common stock as of the date immediately prior to the share determination date. In 2025, consistent with prior-year practice of making grants on or around February 1, the number of shares were determined as of January 31, 2025, with the grant formally being approved on February 1, 2025 by the Committee.

As described in the "Grant of Plan-Based Awards" table below, the annual grant of PSUs granted in 2025 will generally cliff vest on February 1, 2028, subject to certification of Relative TSR performance versus the 2025 peer group over the three-year performance period, and the annual grant of RSUs vest ratably in equal installments on the first, second and third anniversary of February 1, 2025. Except as otherwise noted in the "Potential Payments Upon Termination or Change in Control," awards of PSUs and RSUs are generally subject to the recipient's continued employment through each vesting date. Our Relative TSR goals for PSUs are shown below.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Below Threshold** | **Threshold** | **Target** | **Maximum** |
| Relative TSR rank | <25th Percentile | 25th Percentile | 50th Percentile | ≥75th Percentile |
| Payout (% target)<sup>(1)</sup> | 0% | 50% | 100% | 200% |

---

_____________________

(1)For performance between goals straight-line interpolation will be applied. For performance below threshold (i.e., ranking below the 25th percentile relative to peers), no vesting will occur.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

The Compensation Committee, after considering individual performance and potential, market positioning, and input from ClearBridge, elected to increase the target annual equity award opportunities for certain executives to enhance the market competitiveness and support retention and alignment with long-term shareholder value creation. Half of the increases are delivered in at-risk compensation through PSUs tied to relative TSR performance vs. the compensation peer group. The following executives received increases: Ms. Foster (from $4,900,000 to $5,600,000), Mr. Clemens (from $1,950,000 to $2,600,000), and Mr. Prast (from $1,000,000 to $1,300,000).

---

| | | | |
|:---|:---|:---|:---|
| | | **Equity Mix** | **Equity Mix** |
| **Executive** | **Target Equity Value** | **PSUs** | **RSUs** |
| Suzanne Foster | $5600000 | 50% | 50% |
| Jason Clemens | $2600000 | 50% | 50% |
| Toby Scott Barnhart | $1300000 | 50% | 50% |
| Russell Schuster<sup>(1)</sup> | $1000000 | 50% | 50% |
| Albert Prast | $1300000 | 50% | 50% |

---

_____________________

(1)The table does not include Mr. Schuster's CCO Inducement RSUs, which vest ratably in three equal installments on each anniversary of the grant date, subject to continued employment.

In addition to his annual equity award, on February 1, 2025, per the terms of Mr. Schuster's employment agreement dated November 5, 2024, the Company granted Mr. Schuster an RSU award with an aggregate grant date value of $500,000, with such shares determined based on the 20-trading day volume weighted average price of the Company's common stock as of the day immediately prior to the grant date, in accordance with the Company's historical grant practices (the "CCO Inducement RSUs"). The CCO Inducement RSUs vest ratably in three equal installments on each anniversary of the grant date, subject to Mr. Schuster's continued employment through the applicable vesting date.

<u>Status of Previously Granted PSUs</u>

No prior awards of PSUs were earned or vested during the year ended December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2022 PSUs (Unearned): Our first award of PSUs based on Relative TSR was granted in the first quarter of 2022 and was eligible to vest in the first quarter of 2025. However, no shares vested based on the achievement of the corresponding performance goals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2023 PSUs (Unearned): Our second award of PSUs based on Relative TSR was granted in the first quarter of 2023 and was eligible to vest in the first quarter of 2026. However, no shares vested based on the achievement of the corresponding performance goals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2024 PSUs (Outstanding): Our third award of PSUs based on Relative TSR was granted in the first quarter of 2024 and is eligible to vest in the first quarter of 2027, subject to achievement of the corresponding performance goals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2025 PSUs (Outstanding): Our fourth award of PSUs based on Relative TSR was granted in the first quarter of 2025 and is eligible to vest in the first quarter of 2028, subject to achievement of the corresponding performance goals.

***Item 402(x) of Regulation S-K***

The following information is being provided as required by Item 402(x) of Regulation S-K. The Company's long-standing practice has been to grant equity compensation on a pre-determined schedule at approximately the same time each year, with interim or off-cycle grants being reviewed and approved by the Committee as circumstances warrant. During 2025, the Company did not grant stock options or stock appreciation rights to its employees. The Committee and the Board did not take material nonpublic information into account when determining the timing and terms of equity awards in 2025, and for 2025, we did not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

***Benefits and Perquisites***

Our NEOs are eligible to participate in employee benefit programs available to our employees generally, subject to the terms and conditions of such plans as may be in place from time to time.

---

| | |
|:---|:---|
| **Benefit** | **Key Features** |
| Health & Welfare Plans | ✓Medical, dental, vision, life, disability, health and dependent care flexible spending accounts <br>✓Accidental death and dismemberment benefit plans  |
| Retirement Benefits | ✓Employer-sponsored 401(k) plan through one of our subsidiaries <br>✓Company match is 100% on the first 1% of an employee's contribution, and 50% on the next 2% with maximum employee contributions and employer matches subject to annual federal limits <br>✓Employees are 100% vested on pre-tax deferrals when contributed and participants age 50 or older may contribute additional catch-up contributions based on statutory limits  |
| Non-qualified Deferred Compensation Plan | ✓Deferrals and distributions are made in accordance with the terms of the plan and Section 409A |
| CEO Corporate Apartment | ✓In connection with the Company's establishment of its New York office, the Compensation Committee approved a limited, two-year perquisite for the Chief Executive Officer consisting of reimbursement of costs associated with a corporate apartment in New York metropolitan area. The Committee determined this to be a reasonable and appropriate business expense to support the CEO's transition and reduce the need for frequent travel to New York by enabling the CEO to spend additional time in New York. |

---

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**<u>ADDITIONAL INFORMATION</u>**

***Tax and Accounting Considerations***

Under Code Section 162(m), a publicly held corporation cannot take a federal income tax deduction for compensation exceeding $1 million per person in any taxable year for its chief executive officer, chief financial officer and other three most highly compensated executive officers (each, a "**Covered Person**"). In addition, once an individual becomes a Covered Person for any taxable year, that individual will remain a Covered Person for all future years, including following any termination of employment.

While the Committee considers the anticipated tax treatment to the Company and our executive officers as one factor when reviewing our executive compensation and other compensation programs, the Committee also looks at other factors in making its decisions, as noted above, and retains full authority to approve compensation arrangements for our executive officers that are not fully deductible under Section 162(m) when it believes that other considerations outweigh the tax deductibility of the compensation.

**Compensation Committee Report**

The Committee has reviewed and discussed the Compensation Discussion and Analysis as required by Item 402(b) of Regulation S-K with management. Based on this review and discussions, the Committee recommended to the Board of Directors that this Compensation Discussion and Analysis be included in this Proxy Statement.

Brad Coppens — Chair

Gregory Belinfanti

Susan Weaver, M.D.

David S. Williams III

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**EXECUTIVE COMPENSATION**

The following table sets forth information regarding the compensation awarded to, earned by, or paid to our NEOs during the fiscal years ended December 31, 2025, 2024 and 2023.

**Summary Compensation Table**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and Principal Position** | **Year** | **Salary<br>($)** | **Bonus <br> ($)** | | **Stock** <br> **Awards**<sup>(1)</sup><br> **($)**  | **Option <br> Awards <br> ($)** | **Non-equity** <br> **Incentive Plan** <br> **Compensation**<sup>(2)</sup><br> **($)**  | **All Other** <br> **Compensation**<sup>(3)</sup><br>**($)**  | **Total <br> ($)** |
| &nbsp;&nbsp;&nbsp;Suzanne Foster<sup>(5)</sup><br>*Chief Executive Officer* | 2025 | 1000000 |  |  | 7530880 |  | 1394694 | 330666 | 10256240 |
| &nbsp;&nbsp;&nbsp;Suzanne Foster<sup>(5)</sup><br>*Chief Executive Officer* | 2024 | 561577 |  |  | 6592784 |  | 1236857 | 534 | 8391752 |
| &nbsp;&nbsp;&nbsp;Suzanne Foster<sup>(5)</sup><br>*Chief Executive Officer* | 2023 |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Jason Clemens<br>*Chief Financial Officer* | 2025 | 670000 |  |  | 3496474 |  | 778704 | 10680 | 4955858 |
| &nbsp;&nbsp;&nbsp;Jason Clemens<br>*Chief Financial Officer* | 2024 | 635739 |  |  | 4949552 |  | 744405 | 22530 | 6352226 |
| &nbsp;&nbsp;&nbsp;Jason Clemens<br>*Chief Financial Officer* | 2023 | 520000 |  |  | 1256827 |  | 587808 | 18780 | 2383415 |
| &nbsp;&nbsp;&nbsp;Toby Scott Barnhart<sup>(5)</sup><br>*Chief Operating Officer* | 2025 | 600000 |  |  | 1748251 |  | 697347 | 516 | 3046114 |
| &nbsp;&nbsp;&nbsp;Toby Scott Barnhart<sup>(5)</sup><br>*Chief Operating Officer* | 2024 | 166154 | 187744 |  | 993145 |  |  | 99 | 1347142 |
| &nbsp;&nbsp;&nbsp;Toby Scott Barnhart<sup>(5)</sup><br>*Chief Operating Officer* | 2023 |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Russell Schuster<sup>(5)</sup><br>*Chief Commercial Officer* | 2025 | 450000 | 100000 | (4) | 1892262 |  | 523010 | 8456 | 2973728 |
| &nbsp;&nbsp;&nbsp;Russell Schuster<sup>(5)</sup><br>*Chief Commercial Officer* | 2024 |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Russell Schuster<sup>(5)</sup><br>*Chief Commercial Officer* | 2023 |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Albert Prast<br>*Chief Technology Officer* | 2025 | 450000 |  |  | 1748251 |  | 523010 | 1606 | 2722867 |
| &nbsp;&nbsp;&nbsp;Albert Prast<br>*Chief Technology Officer* | 2024 | 453462 |  |  | 1882494 |  | 515357 | 792 | 2852105 |
| &nbsp;&nbsp;&nbsp;Albert Prast<br>*Chief Technology Officer* | 2023 | 450000 |  |  | 837896 |  | 508680 | 792 | 1797368 |

---

_____________________

(1)The amounts reported in this column for 2025 represent the aggregate grant-date fair value of the restricted stock units granted during the fiscal year ended December 31, 2025, which was determined in accordance with FASB ASC 718. The amounts reported in this column reflect the grant-date fair value of the restricted stock units for accounting purposes and do not represent the actual economic value that may be realized by each NEO. There can be no assurance that these amounts will ever be realized. See note 13, *Stockholders' Equity*, to our consolidated financial statements for the fiscal year ended December 31, 2025 to our Annual Report on Form 10-K for the year ended December 31, 2025 for a discussion of the assumptions used to calculate these values.

(2)The amounts reported in this column for 2025 represent the annual performance-based incentive compensation earned with respect to 2025 by each NEO. The annual performance-based incentive compensation was paid in the first quarter of 2026. For additional information, please see "Compensation Discussion & Analysis — 2025 Compensation Decisions and Outcomes — Annual Incentives" above, and the summary to the "Potential Payments Upon Termination or Change in Control" table below.

(3)The amounts reported as earned by each NEO in this column for 2025 represent the following: (i) for Ms. Foster,$191,640 for reimbursement of costs for a corporate apartment located in the New York metropolitan area, $124,288 for reimbursement of associated income tax relating to such corporate apartment, $10,500 for an employer matching contribution to the Company's 401(k) plan, $2,972 for the value of non-cash compensation, including reimbursement of associated income tax, $750 for an employer matching contribution to the Company's Health Savings Account, and $516 in life insurance premiums; (ii) for Mr. Clemens, $10,500 for an employer matching contribution to the Company's 401(k) plan and $180 in life insurance premiums, (iii) for Mr. Barnhart, $516 in life insurance premiums; (iv) for Mr. Schuster, $5,077 for an employer matching contribution to the Company's 401(k) plan, $2,549 for the value of non-cash compensation, including reimbursement of associated income tax, $664 for an employer matching contribution to the Company's Health Savings Account, and $166 in life insurance premiums; and (v) for Mr. Prast, $1,524 in life insurance premiums, and $82 for the value of non-cash compensation, including reimbursement of associated income tax.

(4)This amount represents the amount paid to Mr. Schuster in respect of his sign-on bonus pursuant to his employment agreement. For additional information, please see "— Narrative to Summary Compensation Table-Executive Employment Agreements" below.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

(5)Ms. Foster and Messrs. Barnhart and Schuster were not employed by the Company in the year ended December 31, 2023 and therefore were not NEOs in that year. Mr. Schuster was not a NEO of the Company in the year ended December 31, 2024.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**Grants of Plan-Based Awards Table**

The following table sets forth grants of plan-based awards to our NEOs as of December 31, 2025.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Estimated Future Payouts<br> Under Non-Equity <br> Incentive Plan Awards** | **Estimated Future Payouts<br> Under Non-Equity <br> Incentive Plan Awards** | **Estimated Future Payouts<br> Under Non-Equity <br> Incentive Plan Awards** | **Estimated Future Payouts <br> Under Equity Incentive <br> Plan Awards** | **Estimated Future Payouts <br> Under Equity Incentive <br> Plan Awards** | **Estimated Future Payouts <br> Under Equity Incentive <br> Plan Awards** | **All Other Stock** <br> **Awards:** <br> **Number of Shares of Stock or Units** <br> **(#)**<sup>(3)</sup> | **Grant Date Fair Value** <br> **of Stock and Option Awards** <br> **($)**<sup>(4)</sup> |
| **Name** | **Grant Date**<sup>(1)</sup> | **Threshold <br> ($)** | **Target <br> ($)** | **Maximum <br> ($)** | **Threshold <br> (#)** | **Target** <br> **(#)**<sup>(2)</sup> | **Maximum <br> (#)** | **All Other Stock** <br> **Awards:** <br> **Number of Shares of Stock or Units** <br> **(#)**<sup>(3)</sup> | **Grant Date Fair Value** <br> **of Stock and Option Awards** <br> **($)**<sup>(4)</sup> |
| Suzanne Foster | February 18, 2025 | 600000 | 1200000 | 2400000 |  |  |  |  |  |
|  | February 1, 2025 |  |  |  |  |  |  | 271090 | 2933194 |
|  | February 1, 2025 |  |  |  | 135545 | 271090 | 542180 |  | 4597686 |
| Jason Clemens | February 18, 2025 | 335000 | 670000 | 1340000 |  |  |  |  |  |
|  | February 1, 2025 |  |  |  |  |  |  | 125863 | 1361838 |
|  | February 1, 2025 |  |  |  | 62932 | 125863 | 251726 |  | 2134636 |
| Toby Scott Barnhart | February 18, 2025 | 300000 | 600000 | 1200000 |  |  |  |  |  |
|  | February 1, 2025 |  |  |  |  |  |  | 62932 | 680924 |
|  | February 1, 2025 |  |  |  | 31466 | 62932 | 125864 |  | 1067327 |
| Russell Schuster | February 18, 2025 | 225000 | 450000 | 900000 |  |  |  |  |  |
|  | February 1, 2025 |  |  |  |  |  |  | 50597 | 547460 |
|  | February 1, 2025 |  |  |  |  |  |  | 48409 | 523785 |
|  | February 1, 2025 |  |  |  | 24205 | 48409 | 96818 |  | 821017 |
| Albert Prast | February 18, 2025 | 225000 | 450000 | 900000 |  |  |  |  |  |
|  | February 1, 2025 |  |  |  |  |  |  | 62932 | 680924 |
|  | February 1, 2025 |  |  |  | 31466 | 62932 | 125864 |  | 1067327 |

---

_____________________

(1)Annual cash bonus opportunities approved by the Committee on February 18, 2025 were made pursuant to the Company's annual bonus plan. For Ms. Foster and Messrs. Clemens, Barnhart and Prast, equity awards granted on February 1, 2025 consisted of annual grants of service-based restricted stock units and performance-based restricted stock units which were made pursuant to the 2019 Stock Incentive Plan. For Mr. Schuster, equity awards granted on February 1, 2025 consisted of the CCO Inducement RSUs, and an annual grant of service-based restricted stock units and performance-based restricted stock units, each of which were made pursuant to the 2019 Stock Incentive Plan.

(2)Restricted stock units reported in this column are earned based upon the achievement of certain relative total shareholder return goals as defined, and, if earned, vest on the third anniversary of February 1, 2025.

(3)Restricted stock units reported in this column are eligible to vest 1/3rd on each of the first, second and third anniversaries of February 1, 2025.

(4)The amounts reported in this column represent the aggregate grant-date fair value of the restricted stock units granted during the fiscal year ended December 31, 2025, which was determined in accordance with FASB ASC 718. These amounts reflect the grant-date fair value of the restricted stock units for accounting purposes and do not represent the actual economic value that may be realized by each named executive officer. There can be no assurance that these amounts will ever be realized. See note 13, *Stockholders' Equity*, to our consolidated financial statements for the fiscal year ended December 31, 2025 to our Annual Report on Form 10-K for the year ended December 31, 2025 for a discussion of the assumptions used to calculate these values.

**Narrative to Summary Compensation Table and Grants of Plan-Based Awards Table**

***Executive Employment Agreements***

Certain of the compensation paid to our NEOs reflected in the summary compensation table was provided pursuant to employment agreements with the Company or one of its subsidiaries, which are summarized below. For a discussion of the severance pay and other benefits to be provided to our NEOs in connection with a termination of employment and/or a change in control, please see "Potential Payments Upon Termination or Change In Control" below. Please also see "Compensation Discussion & Analysis-Compensation at a Glance" above for an explanation of the amount of salary and bonus in proportion to total compensation for our NEOs.

**Suzanne Foster.** Ms. Foster is party to an employment agreement with the Company, dated April 10, 2024, pursuant to which Ms. Foster is entitled to receive an annual base salary, which for 2025 was $1,000,000 (which amount is subject to increase from time to time) and is eligible to receive a target annual incentive bonus, which for 2025 was equal to 120%

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

of her base salary, based on the achievement of annual Company performance objectives for the applicable fiscal year, subject to continued employment through the payment date. Ms. Foster is also eligible to participate in the Company's employee benefit programs offered to similarly situated employees of the Company, and she is eligible to receive annual equity incentive grants, subject to the approval of, and terms and conditions established by, the Committee. In connection with her employment agreement, Ms. Foster entered into a restrictive covenant agreement, which includes a 24-month post-termination non-compete, a 24-month post-termination non-solicit of the employees, consultants, clients, customers and other business relationships of the Company and its affiliates, and an indefinite covenant against making any disparaging or defamatory comments regarding the Company or any of its affiliates.

**Jason Clemens.** Mr. Clemens is party to an employment agreement with the Company, dated May 1, 2020, as amended on April 15, 2024 and December 9, 2024, pursuant to which Mr. Clemens is entitled to receive an annual base salary, which for 2025 was $670,000 (which amount is subject to increase from time to time) and is eligible to receive a target annual incentive bonus, which for 2025 was equal to 100% of his base salary, based on the achievement of annual Company performance objectives for the applicable fiscal year, subject to continued employment through the applicable payment date. Mr. Clemens is also eligible to participate in the Company's employee benefit programs offered to similarly situated employees and to receive annual equity incentive grants, subject to the approval of, and terms and conditions established by, the Committee. In connection with his employment agreement, Mr. Clemens entered into a restrictive covenant agreement, which includes a 12-month post-termination non-compete, a 12-month post-termination non-solicit of the employees, consultants, clients, customers and other business relationships of the Company and its affiliates and an indefinite covenant against making any disparaging or defamatory comments regarding the Company or any of its affiliates.

**Toby Scott Barnhart.** Mr. Barnhart is party to an employment agreement with the Company, dated August 1, 2024, pursuant to which Mr. Barnhart is entitled to receive an annual base salary, which for 2025 was $600,000 (which amount is subject to increase from time to time), and he is eligible to receive a target annual incentive bonus, which for 2025 was equal to 100% of his base salary, based on the achievement of annual Company performance objectives for the applicable fiscal year, subject to continued employment through the applicable payment date. Mr. Barnhart is also eligible to participate in the Company's employee benefit programs offered to similarly situated employees of the Company, and he is eligible to receive annual equity incentive grants, subject to the approval of, and terms and conditions established by, the Committee. In connection with his employment agreement, Mr. Barnhart entered into a restrictive covenant agreement, which includes an 18-month post-termination non-compete, a 24-month post-termination non-solicit of the employees, consultants, clients, customers and other business relationships of the Company and its affiliates, and an indefinite covenant against making any disparaging or defamatory comments regarding the Company or any of its affiliates.

**Russell Schuster.** Mr. Schuster is party to an employment agreement with the Company, dated November 5, 2024, pursuant to which Mr. Schuster is entitled to receive an annual base salary, which for 2025 was $450,000 (which amount is subject to increase from time to time), and he is eligible to receive a target annual incentive bonus, which for 2025 was equal to 100% of his base salary, based on the achievement of annual Company performance objectives for the applicable fiscal year, subject to continued employment through the applicable payment date. Mr. Schuster is also eligible to participate in the Company's employee benefit programs offered to similarly situated employees and is eligible to receive annual equity incentive grants, subject to the approval of, and terms and conditions established by, the Committee. In February 2025, in connection with his commencement of employment, the Company paid Mr. Schuster a cash sign-on bonus in an amount equal to $100,000, which was granted subject to repayment in full in the event that Mr. Schuster's employment was terminated by the Company for "cause" or by Mr. Schuster without "good reason" (as each such term is defined in his employment agreement), within the one-year period following his start date of January 2, 2025. In connection with his employment agreement, Mr. Schuster entered into a restrictive covenant agreement, which includes a 12-month post-termination non-compete, a 12-month post-termination non-solicit of the employees, consultants, clients, customers and other business relationships of the Company and its affiliates, and an indefinite covenant against making any disparaging or defamatory comments regarding the Company or any of its affiliates.

**Albert Prast.** Mr. Prast is party to an employment agreement with the Company, dated October 30, 2024 (which superseded Mr. Prast's prior employment agreement with the Company, dated July 24, 2023), pursuant to which Mr. Prast is entitled to receive an annual base salary, which for 2025 was $450,000 (which amount is subject to increase from time to time), and is eligible to receive a target annual incentive bonus, which for 2025 was equal to 100% of his base salary, based on the achievement of annual Company performance objectives for the applicable fiscal year, subject to continued employment through the applicable payment date. Mr. Prast is also eligible to participate in the Company's employee benefit programs offered to similarly situated employees and is eligible to receive annual equity incentive grants, subject to the approval of, and terms and conditions established by, the Committee. In connection with his employment agreement,

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

Mr. Prast entered into a restrictive covenant agreement, which includes an 18-month post-termination non-compete, a 24-month post-termination non-solicit of the employees, consultants, clients, customers and other business relationships of the Company and its affiliates, and an indefinite covenant against making any disparaging or defamatory comments regarding the Company or any of its affiliates.

***Stock Incentive Plan***

The Company maintains the 2019 Stock Incentive Plan, which was originally adopted by the Board on October 14, 2019 and approved by our stockholders on November 7, 2019, and was amended and restated as adopted by the Board on June 21, 2021 and approved by our stockholders on July 27, 2021, and subsequently amended and restated in its current form as adopted by the Board on April 12, 2024 and approved by our stockholders on June 20, 2024. Pursuant to the Plan, the Committee may award a broad variety of incentive equity awards, including options to purchase shares of the Company, shares of restricted stock, and restricted stock units. Awards are subject to the terms and conditions of the applicable award agreement entered into with a recipient at the time of grant and the terms and conditions of the Plan.

**2025 Equity Awards.** On February 1, 2025, the Committee approved the grants of restricted stock units to the NEOs pursuant to the Plan and the applicable form of award agreement, with the vesting commencement date as of February 1, 2025. With the exception of the CCO Inducement RSUs, one-half of the restricted stock units are subject to time-based vesting criteria and are eligible to vest 1/3rd on each of the first three anniversaries of February 1, 2025, subject to the executive's continued employment through each applicable vesting date. The other half of the restricted stock units are subject to performance-based vesting criteria and are eligible to vest in the first quarter of 2028 subject to the achievement of relative total shareholder return metrics compared to peer companies over the performance period ending on February 1, 2028, with the percentage of restricted stock units that vest equal to (i) 50% for performance at the 25th percentile, (ii) 100% for performance at the 50th percentile, and (iii) 200% for performance at the 75th percentile, with linear interpolation between performance threshold. No portion of the restricted stock units that are subject to performance-based vesting criteria will vest in the event that performance is below the 25th percentile. The CCO Inducement RSUs granted to Mr. Schuster are described in the "Grant of Plan-Based Awards" table.

***Health and Welfare Plan***

Our NEOs are generally eligible to participate in the employee benefit plans, including medical, dental, vision, life, disability, health and dependent care flexible spending accounts and accidental death and dismemberment benefit plans maintained by the Company or one of our subsidiaries, in each case on the same basis as all of our other employees.

***Retirement Plan***

One of our subsidiaries sponsors a retirement plan intended to qualify for favorable tax treatment under Section 401(a) of the Internal Revenue Code of 1986, as amended (the "**Code**"), containing a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the Code, for the benefit of our employees, including our NEOs. Participants may make pre-tax contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit on pre-tax contributions under the Code. Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for catch-up contributions. All employee contributions are allocated to each participant's individual account and are then invested in selected investment alternatives according to the participant's directions. Pre-tax contributions by participants to the plan and the income earned on those contributions are generally not taxable to participants until withdrawn, and participant contributions are held in trust as required by law. No minimum benefit is provided under the plan. An employee is 100% vested in his or her pre-tax deferrals when contributed. We currently make an employer matching contribution of 100% on the first 1% of an employee's contribution and 50% on the next 2% of an employee's contribution.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**Outstanding Equity Awards at Fiscal Year End Table**

The following table sets forth outstanding equity awards held by each of our NEOs as of December 31, 2025.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Option Awards** | **Option Awards** | **Option Awards** | **Option Awards** | **Stock Awards** | **Stock Awards** | **Stock Awards** | **Stock Awards** |
| **Name** | **Grant Date** | **Number of Securities <br> Underlying <br> Unexercised <br> Options <br>(#) <br> Exercisable** | **Number of Securities <br> Underlying <br> Unexercised <br> Options<br>(#) <br> Unexercisable** | **Option <br> Exercise <br> Price <br> ($)** | **Option <br> Expiration <br> Date** | **Equity Incentive Plan Awards: Number of Unearned Shares or Other Rights That Have Not Vested (#)** | **Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested <br> ($)** | **Number of Shares <br> or Units of Stock <br> That Have Not <br> Vested<br>(#)** | **Market Value of** <br> **Shares or Units** <br> **of Stock That** <br> **Have Not Vested** <br> **($)**<sup>(13)</sup> |
| Suzanne Foster | May 20, 2024<sup>(1)</sup> |  |  |  |  |  |  | 46886 | 466985 |
|  | May 20, 2024<sup>(2)</sup> |  |  |  |  |  |  | 153160 | 1525474 |
|  | May 20, 2024<sup>(3)</sup> |  |  |  |  | 459480 | 4576421 |  |  |
|  | February 1, 2025<sup>(4)</sup> |  |  |  |  |  |  | 271090 | 2700056 |
|  | February 1, 2025<sup>(5)</sup> |  |  |  |  | 542180 | 5400113 |  |  |
| Jason Clemens | March 8, 2023<sup>(6)</sup> |  |  |  |  |  |  | 11991 | 119430 |
|  | March 8, 2023<sup>(7)</sup> |  |  |  |  | 17985 | 179131 |  |  |
|  | February 5, 2024<sup>(8)</sup> |  |  |  |  |  |  | 92742 | 923710 |
|  | March 18, 2024<sup>(9)</sup> |  |  |  |  |  |  | 85587 | 852447 |
|  | March 31, 2024<sup>(10)</sup> |  |  |  |  | 111290 | 1108448 |  |  |
|  | June 20, 2024<sup>(10)</sup> |  |  |  |  | 166934 | 1662663 |  |  |
|  | February 1, 2025<sup>(4)</sup> |  |  |  |  |  |  | 125863 | 1253595 |
|  | February 1, 2025<sup>(5)</sup> |  |  |  |  | 251726 | 2507191 |  |  |
| Toby Scott Barnhart | September 23, 2024<sup>(11)</sup> |  |  |  |  |  |  | 59595 | 593566 |
|  | February 1, 2025<sup>(4)</sup> |  |  |  |  |  |  | 62932 | 626803 |
|  | February 1, 2025<sup>(5)</sup> |  |  |  |  | 125864 | 1253605 |  |  |
| Russell Schuster | February 1, 2025<sup>(4)</sup> |  |  |  |  |  |  | 50597 | 503946 |
|  | February 1, 2025<sup>(4)</sup> |  |  |  |  |  |  | 48409 | 482154 |
|  | February 1, 2025<sup>(5)</sup> |  |  |  |  | 96818 | 964307 |  |  |
| Albert Prast | February 1, 2021<sup>(12)</sup> | 180021 |  | 8.50 | March 1, 2030 |  |  |  |  |
|  | February 1, 2021<sup>(12)</sup> | 89451 |  | 4.38 | August 1, 2026 |  |  |  |  |
|  | March 8, 2023<sup>(6)</sup> |  |  |  |  |  |  | 7994 | 79620 |
|  | March 8, 2023<sup>(7)</sup> |  |  |  |  | 11990 | 119420 |  |  |
|  | February 5, 2024<sup>(8)</sup> |  |  |  |  |  |  | 47560 | 473698 |
|  | March 31, 2024<sup>(10)</sup> |  |  |  |  | 57072 | 568437 |  |  |
|  | June 20, 2024<sup>(10)</sup> |  |  |  |  | 85606 | 852636 |  |  |
|  | February 1, 2025<sup>(4)</sup> |  |  |  |  |  |  | 62932 | 626803 |
|  | February 1, 2025<sup>(5)</sup> |  |  |  |  | 125864 | 1253605 |  |  |

---

_____________________

(1)Represents a grant of restricted stock units eligible to vest on May 20, 2026. For additional information, see "—Narrative to Summary Compensation Table and Grants of Plan-Based Awards Table-Long-Term Incentives-2019 Stock Incentive Plan" above.

(2)Represents a grant of restricted stock units eligible to vest 50% on each of May 20, 2026 and May 20, 2027. For additional information, see "—Narrative to Summary Compensation Table and Grants of Plan-Based Awards Table-Long-Term Incentives-2019 Stock Incentive Plan" above.

(3)Represents a grant of restricted stock units eligible to vest on May 20, 2027 based upon the achievement of certain total shareholder goals, as defined. For purposes of this disclosure and in reliance on SEC rules, we have reasonably estimated that this award was tracking to achieve above target levels of performance as of December 31, 2025, the award is presented at maximum achievement (200% of target). For additional information, see "—Narrative to Summary Compensation Table—Long-Term Incentives—2019 Stock Incentive Plan" above.

(4)Represents grants of restricted stock units eligible to vest 1/3rd on each of the first, second and third anniversaries of February 1, 2025. For additional information, see "—Narrative to Summary Compensation Table and Grants of Plan-Based Awards Table-Long-Term Incentives-2019 Stock Incentive Plan" above.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

(5)Represents grants of restricted stock units eligible to vest on February 1, 2028 based upon the achievement of certain total shareholder goals, as defined. For purposes of this disclosure and in reliance on SEC rules, we have reasonably estimated that this award was tracking to achieve above target levels of performance as of December 31, 2025, and accordingly, the award is presented at maximum achievement (200% of target). For additional information, see "—Narrative to Summary Compensation Table—Long-Term Incentives—2019 Stock Incentive Plan" above.

(6)Represents grants of restricted stock units eligible to vest on February 1, 2026. For additional information, see "—Narrative to Summary Compensation Table and Grants of Plan-Based Awards Table-Long-Term Incentives-2019 Stock Incentive Plan" above.

(7)Represents grants of restricted stock units eligible to vest on February 1, 2026 based upon the achievement of certain total shareholder goals, as defined. For purposes of this disclosure and in reliance on SEC rules, we have reasonably estimated that this award was tracking to achieve below threshold levels of performance as of December 31, 2025, and accordingly, the award is presented at threshold achievement (50% of target). For additional information, see "—Narrative to Summary Compensation Table—Long-Term Incentives—2019 Stock Incentive Plan" above.

(8)Represents grants of restricted stock units eligible to vest 50% on each of February 1, 2026 and February 1, 2027. For additional information, see "—Narrative to Summary Compensation Table and Grants of Plan-Based Awards Table-Long-Term Incentives-2019 Stock Incentive Plan" above.

(9)Represents grants of restricted stock units eligible to vest 50% on each of March 18, 2026 and March 18, 2027. For additional information, see "—Narrative to Summary Compensation Table and Grants of Plan-Based Awards Table-Long-Term Incentives-2019 Stock Incentive Plan" above.

(10)Represents grants of restricted stock units eligible to vest on February 1, 2027 based upon the achievement of certain total shareholder goals, as defined. For purposes of this disclosure and in reliance on SEC rules, we have reasonably estimated that this award was tracking to achieve above target levels of performance as of December 31, 2025, the award is presented at maximum achievement (200% of target). For additional information, see "—Narrative to Summary Compensation Table—Long-Term Incentives—2019 Stock Incentive Plan" above.

(11)Represents grants of restricted stock units eligible to vest 50% on each of September 19, 2026 and September 19, 2027. For additional information, see "—Narrative to Summary Compensation Table and Grants of Plan-Based Awards Table-Long-Term Incentives-2019 Stock Incentive Plan" above.

(12)Represents Company stock options substituted for previously granted AeroCare stock options in connection with the AeroCare transaction, which were fully vested as of February 1, 2021.

(13)As of December 31, 2025, the fair market value of a share of our Common Stock was $9.96.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**Option Exercises and Stock Vested Table**

The following table sets forth information concerning the vesting of stock awards held by our NEOs during the fiscal year ended December 31, 2025. There were no stock option exercises by our NEOs during the fiscal year ended December 31, 2025.

---

| | | |
|:---|:---|:---|
| | **Stock Awards** | **Stock Awards** |
| **Name** | **Number of Shares <br> Acquired on Vesting <br> (#)** | **Value Realized <br> on Vesting <br> ($)** |
| Suzanne Foster<sup>(1)</sup> | 123465 | 1142051 |
| Jason Clemens<sup>(2)</sup> | 113710 | 1148985 |
| Toby Scott Barnhart<sup>(3)</sup> | 29797 | 264895 |
| Russell Schuster |  |  |
| Albert Prast<sup>(4)</sup> | 52644 | 539075 |

---

_____________________

(1)Represents restricted stock units that vested on May 20, 2025, on which date the fair market value of a share of our Common Stock was $9.25. Ms. Foster received a total of 74,882 shares of our Common Stock in connection with the net settlement of her vested stock awards to cover required tax withholding obligations.

(2)Represents restricted stock units that vested on February 1, 2025 and March 18, 2025, on which dates the fair market value of a share of our Common Stock was $10.24 and $9.88, respectively. Mr. Clemens received a total of 73,902 shares of our Common Stock in connection with the net settlement of his vested stock awards to cover required tax withholding obligations.

(3)Represents restricted stock units that vested on September 19, 2025, on which date the fair market value of a share of our Common Stock was $8.89. Mr. Barnhart received a total of 22,542 shares of our Common Stock in connection with the net settlement of his vested stock awards to cover required tax withholding obligations.

(4)Represents restricted stock units that vested on February 1, 2025, on which date the fair market value of a share of our Common Stock was $10.24. Mr. Prast received a total of 39,112 shares of our Common Stock in connection with the net settlement of his vested stock awards to cover required tax withholding obligations.

**Pension Benefits**

We do not currently sponsor or maintain any defined benefit pension plans or other benefit plans providing specified retirement payments and benefits.

**Non-Qualified Deferred Compensation**

On November 17, 2023, the Company adopted the AdaptHealth LLC Non-Qualified Deferred Compensation Plan (the "NQDC Plan"), an unfunded, non-qualified deferred compensation plan. Participation in the NQDC Plan is limited to a select group of management and highly compensated employees, including NEOs of the Company. The NQDC Plan was effective as of January 1, 2024.

Under the NQDC Plan, participants may elect to defer receipt of between 1% and 80% of their base salary and between 1% to 100% of their annual cash bonus (other than any performance-based bonus). The Company may make contributions to the NQDC Plan in its sole discretion, but did not make any contributions on behalf of any NEOs during 2025. Participants may receive distributions of their account balances in either a lump sum or in annual installments upon either (i) a specified date, (ii) a separation from service, (iii) due to an unforeseeable emergency, or (iv) due to death or disability. Participants may select investment funds from a broad range of options. Earnings and losses on each account are determined based on the performance of the investment funds selected by the participant.

The following table sets forth information concerning participant contributions made by our NEOs to the NQDC Plan and other activity related to the NQDC Plan during the fiscal year ended December 31, 2025.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Aggregate balance as of December 31, 2024**<br> **($)**  | **Executive contributions in the last FY<br>($)** | **Registrant contributions in the last FY<br>($)** | **Aggregate earnings in the last FY**<sup>(1)</sup><br> **($)**  | **Aggregate withdrawals/distributions<br> ($)** | **Aggregate balance as of December 31, 2025**<br> **($)**  |
| Suzanne Foster |  |  |  |  |  |  |
| Jason Clemens | 26200 | 56555 |  | 13126 |  | 95881 |
| Toby Scott Barnhart |  |  |  |  |  |  |
| Russell Schuster |  |  |  |  |  |  |
| Albert Prast |  |  |  |  |  |  |

---

_____________________

(1)Represents earnings on Mr. Clemens' account balance for 2025. This amount is not included in compensation reported in the Summary Compensation Table because the earnings are not preferential or above-market.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**Potential Payments Upon Termination or Change in Control**

The following summaries describe the potential payments and benefits that we would provide to our NEOs in connection with certain terminations of employment and/or change in control of the Company.

**Severance Pay & Benefits**

Other than as set forth below, and specifically excluding any benefits under employee benefit plans generally available to our employees, we did not offer or have in place for our NEOs any formal retirement, severance or similar compensation programs providing for additional benefits or payments in connection with a termination of employment, change in job responsibility or change in control as of December 31, 2025.

**Suzanne Foster.** Pursuant to her employment agreement, if Ms. Foster's employment is terminated by the Company without "cause" or by Ms. Foster for "good reason" (as such terms are defined in her employment agreement) (either such termination, a "qualifying termination"), subject to her execution and non-revocation of a general release of claims in favor of the Company and its affiliates and continued compliance with restrictive covenants, Ms. Foster is entitled to receive (i) any unpaid annual bonus in respect of any completed fiscal year that has ended prior to the date of such termination, (ii) continued payment of base salary for a period of 18 months following such date of termination (the "CEO Ordinary Severance Term") (or, if such termination occurs on or within 24 months following the consummation of a change in control (as defined in Ms. Foster's employment agreement), 24 months following such date of termination (the "CEO Enhanced Severance Term" and, collectively with the CEO Ordinary Severance Term, the "CEO Severance Term")), (iii) an amount equal to 1.5 times her then-current target annual bonus (or, if such termination occurs on or within 24 months following the consummation of a change in control, 2.0 times her then-current target annual bonus), payable in substantially equal installments during the applicable CEO Severance Term in accordance with regular payroll practices, (iv) continued vesting of the Inducement RSUs (as defined in her employment agreement) during the applicable CEO Severance Term without regard to a continued employment requirement, and (v) continuation of health insurance coverage pursuant to COBRA at the same rate which applies for active employees during the applicable CEO Severance Term (to the extent permitted by applicable law). Upon a qualifying termination within the 24-month period following a change in control or if Ms. Foster's employment is terminated due to her death or disability (as such term is defined in her employment agreement), all outstanding restricted stock units (including the Inducement RSUs) will vest as of the date of such termination, with awards subject to performance conditions vesting based on the greater of (x) actual performance through the termination date upon a qualifying termination (or, at target performance if actual performance is not determinable) or (y) the greater of actual performance and target upon a termination due to death or disability.

**Jason Clemens.** Pursuant to his employment agreement, if Mr. Clemens' employment is terminated by the Company without "cause" or by Mr. Clemens for "good reason" (as such terms are defined in his employment agreement), subject to his execution and non-revocation of a general release of claims in favor of the Company and its affiliates and continued compliance with restrictive covenants, Mr. Clemens is entitled to receive (i) any unpaid annual bonus in respect of any completed fiscal year that has ended prior to the date of such termination and any accrued but unused vacation or other paid time off, (ii) continued payment of base salary for a period of 18 months following such date of termination, (iii) an amount equal to his then-current target annual bonus, prorated for the number of days Mr. Clemens was employed during the year of termination, payable on the regular payment date for annual bonuses earned by the Company's senior management, and (iv) continued employee benefits for the period of salary continuation.

**Toby Scott Barnhart.** Pursuant to his employment agreement, if Mr. Barnhart's employment is terminated by the Company without "cause" or by Mr. Barnhart for "good reason" (as such terms are defined in his employment agreement) (either such termination, a "qualifying termination"), subject to his execution and non-revocation of a general release of claims in favor of the Company and its affiliates and continued compliance with restrictive covenants, Mr. Barnhart is entitled to receive (i) any unpaid annual bonus in respect of any completed fiscal year that has ended prior to the date of such termination, (ii) continued payment of base salary for a period of 18 months following such date of termination, (iii) an amount equal to 1.5 times his then-current target annual bonus, payable in substantially equal installments during the 18-month period following such date of termination in accordance with regular payroll practices, (iv) if such termination occurs prior to the three-year anniversary of his start date (which occurred on September 23, 2024), continued vesting of the Inducement RSUs (as defined in his employment agreement) during the 18-month period following termination without regard to a continued employment requirement, and (v) up to 18 months' continuation of health insurance coverage pursuant to COBRA at the same rate which applies for active employees. Upon a termination of Mr. Barnhart's employment by the Company without cause within the 24-month period following a change in control (as defined in his employment agreement), all outstanding restricted stock units (including the Inducement RSUs) will vest as of the date of

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

such termination, with awards subject to performance conditions vesting based on actual performance through the termination date (or, at target performance if actual performance is not determinable).

**Russell Schuster.** Pursuant to his employment agreement, if Mr. Schuster's employment is terminated by the Company without "cause" or by Mr. Schuster for "good reason" (as such terms are defined in his employment agreement) (either such termination, a "qualifying termination"), subject to his execution and non-revocation of a general release of claims in favor of the Company and its affiliates and continued compliance with restrictive covenants, Mr. Schuster is entitled to receive (i) any unpaid annual bonus in respect of any completed fiscal year that has ended prior to the date of such termination, (ii) continued payment of base salary for a period of 12 months following such date of termination, (iii) if such qualifying termination (or a termination due to Mr. Schuster's death or disability (as such term is defined in his employment agreement)) occurs on or after April 1 of the applicable year of termination, a prorated annual bonus payable in respect of the calendar year of such termination based on actual performance, payable at such time annual bonuses are generally paid to other senior executives of the Company, and (iv) up to 12 months' continuation of health insurance coverage pursuant to COBRA at the same rate which applies for active employees.

**Albert Prast.** Pursuant to his employment agreement, if Mr. Prast's employment is terminated by the Company without "cause" or by Mr. Prast for "good reason" (as such terms are defined in his employment agreement) (either such termination, a "qualifying termination"), subject to his execution and non-revocation of a general release of claims in favor of the Company and its affiliates and continued compliance with restrictive covenants, Mr. Prast is entitled to receive (i) any unpaid annual bonus in respect of any completed fiscal year that has ended prior to the date of such termination, (ii) continued payment of base salary for a period of 18 months following such date of termination, (iii) if such qualifying termination (or a termination due to Mr. Prast's death or disability (as such term is defined in his employment agreement)) occurs on or after April 1 of the applicable year of termination, a prorated annual bonus payable in respect of the calendar year of such termination based on actual performance, payable at such time annual bonuses are generally paid to other senior executives of the Company, and (iv) up to 18 months' continuation of health insurance coverage pursuant to COBRA at the same rate which applies for active employees.

**Stock Incentive Plan**

The 2019 Stock Incentive Plan provides that in the event of a significant "corporate event," as defined therein, each outstanding award will be treated in a manner as determined by the administrator. The Plan further provides for "double-trigger" vesting, such that any award that is assumed or substituted in connection with a "change in control," as defined therein, will immediately vest as of the date the participant holding the award experiences an involuntary termination by the Company other than for cause in connection with, or within two years following, such change in control. As described in the immediately preceding section, each of Ms. Foster and Mr. Barnhart are entitled to additional vesting protection upon certain terminations of employment.

**Potential Payments Upon Termination or Change in Control**

The information in the table below describes and quantifies certain estimated compensation that would have become payable to our NEOs following a change in control of the Company and/or certain terminations of employment of our NEOs assuming that the change in control and/or termination of employment occurred as of December 31, 2025.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Cash <br> Severance <br> Payment <br> ($)** | **Continued <br> Benefits <br> ($)** | **Continued <br> Benefits <br> ($)** | **Value of** <br> **Accelerated** <br> **Equity** <br> **Awards**<sup>(1)</sup><br> **($)**  | **Total <br> ($)** |
| **Suzanne Foster** | | | | | |
| &nbsp;&nbsp;&nbsp;*Termination by the Company without cause* | 3300000 | 27651 | <sup>(2)</sup> | 4280669 | 7608320 |
| &nbsp;&nbsp;&nbsp;*Termination by the Executive for good reason* | 3300000 | 27651 | <sup>(2)</sup> | 4280669 | 7608320 |
| &nbsp;&nbsp;&nbsp;*Termination by the Company without cause in connection with a change in control* | 4400000 | 27651 | <sup>(2)</sup> | 14669048 | 19096699 |
| &nbsp;&nbsp;&nbsp;*Termination upon death or disability* |  |  |  | 14669048 | 14669048 |
| **Jason Clemens** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;*Termination by the Company without cause* | 1675000 | 36637 | <sup>(2)</sup> |  | 1711637 |
| &nbsp;&nbsp;&nbsp;*Termination by the Executive for good reason* | 1675000 | 36637 | <sup>(2)</sup> |  | 1711637 |
| &nbsp;&nbsp;&nbsp;*Termination by the Company without cause in connection with a change in control* | 1675000 | 36637 | <sup>(2)</sup> | 8606615 | 10318252 |
| **Toby Scott Barnhart** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;*Termination by the Company without cause* | 1800000 | 26407 | <sup>(2)</sup> | 296778 | 2123185 |
| &nbsp;&nbsp;&nbsp;*Termination by the Executive for good reason* | 1800000 | 26407 | <sup>(2)</sup> | 296778 | 2123185 |
| &nbsp;&nbsp;&nbsp;*Termination by the Company without cause in connection with a change in control* | 1800000 | 26407 | <sup>(2)</sup> | 2473974 | 4300381 |
| **Russell Schuster** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;*Termination by the Company without cause* | 973010 | 18434 | <sup>(2)</sup> |  | 991444 |
| &nbsp;&nbsp;&nbsp;*Termination by the Executive for good reason* | 973010 | 18434 | <sup>(2)</sup> |  | 991444 |
| &nbsp;&nbsp;&nbsp;*Termination by the Company without cause in connection with a change in control* | 973010 | 18434 | <sup>(2)</sup> | 1950407 | 2941851 |
| &nbsp;&nbsp;&nbsp;*Termination upon death or disability* | 523010 |  |  |  | 523010 |
| **Albert Prast** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;*Termination by the Company without cause* | 1198010 | 26377 | <sup>(2)</sup> |  | 1224387 |
| &nbsp;&nbsp;&nbsp;*Termination by the Executive for good reason* | 1198010 | 26377 | <sup>(2)</sup> |  | 1224387 |
| &nbsp;&nbsp;&nbsp;*Termination by the Company without cause in connection with a change in control* | 1198010 | 26377 | <sup>(2)</sup> | 3974219 | 5198606 |
| &nbsp;&nbsp;&nbsp;*Termination upon death or disability* | 523010 |  |  |  | 523010 |

---

_____________________

(1)For the purposes of calculating the value of accelerated equity awards under the 2019 Stock Incentive Plan in connection with (i) with respect to all NEOs, a termination of employment by the Company without cause in connection with a change in control and, in addition, with respect to a termination of Ms. Foster's employment due to death or disability, and (ii) with respect to Ms. Foster and Mr. Barnhart, a termination by the Company without cause or by the executive for good reason, and in reliance on SEC rules, we have assumed that any equity awards subject to performance-based vesting criteria were assumed or substituted based on a reasonable estimate of how the achievement of the equity awards were tracking compared to target levels of performance as of December 31, 2025.

(2)The amounts reported in this column for Ms. Foster, Mr. Clemens, Mr. Barnhart and Mr. Prast reflect continued medical benefits for an 18-month period. The amounts reported in this column for Mr. Schuster reflect continued medical benefits for a 12-month period.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**Director Compensation**

The following table sets forth the material terms of the compensation received by each of our non-employee directors for the year ended December 31, 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Fees Earned or** <br> **Paid in Cash ($)**<sup>(1)</sup> | | **Stock Awards** <br> **($)**<sup>(2)</sup> | **Total <br> ($)** |
| Dale Wolf | 190000 |  | 201079 | 391079 |
| Terence Connors | 150000 |  | 201079 | 351079 |
| Susan Weaver, M.D. | 120000 |  | 201079 | 321079 |
| Bradley Coppens | 130000 |  | 201079 | 331079 |
| David S. Williams III | 120000 |  | 201079 | 321079 |
| Ted Lundberg | 135605 | (3) | 201079 | 336684 |
| Greg Belinfanti | 124810 | (4) | 201079 | 325889 |
| Diana Nole | 120000 |  | 201079 | 321079 |

---

_____________________

(1)For the year ended December 31, 2025, each of our non-employee directors (with the exception of Mr. Lundberg and Mr. Belinfanti) received cash payments totaling $100,000. As noted in footnotes 3 and 4 below, the amounts reported for Mr. Lundberg and Mr. Belinfanti include the amount of the third and fourth quarter portions of their cash retainers that each of them elected to receive in the form of deferred restricted stock units (the "Deferred RSUs") in accordance with the Company's Non-Employee Director Fee Deferral Policy, as described in more detail in "—Narrative to Director Compensation" below. The amounts reported for each of Mr. Wolf, Mr. Connors and Mr. Coppens include additional cash payments totaling $70,000, $40,000 and $10,000, respectively, representing their annual retainer fees for their service as our Chairman, and chairs of our audit committee and compensation committee, respectively. The amounts reported for each of Mr. Wolf, Mr. Connors, Dr. Weaver, Mr. Coppens, Mr. Williams and Ms. Nole include additional cash payments totaling $20,000, $10,000, $20,000, $20,000, $20,000 and $20,000, respectively, representing fees for their service on certain committees.

(2)Represents the aggregate grant-date fair value for accounting purposes, in accordance with FASB ASC 718, of 21,346 restricted stock units to each of our non-employee directors, granted pursuant to the Plan and approved by our compensation committee on June 26, 2025 and will vest 100% on the occurrence of our 2026 annual meeting of stockholders. Mr. Lundberg and Mr. Belinfanti each elected to receive their annual awards in the form of Deferred RSUs in accordance with the Company's Non-Employee Director Fee Deferral Policy. For additional information, see "—Narrative to Director Compensation" below.

(3)Mr. Lundberg received cash payments totaling $60,000, including $50,000 representing the portion of Mr. Lundberg's retainer fees paid in cash plus $10,000 representing cash fees for Mr. Lundberg's service as the chair of our corporate compliance and governance committee and a member of our audit committee. Pursuant to the Company's Non-Employee Director Fee Deferral Policy, Mr. Lundberg elected to receive the deferred restricted stock units in lieu of his third and fourth quarter cash retainer fee and amounts for his committee service. Pursuant to his election, in addition to his annual grant, Mr. Lundberg was granted 8,026 Deferred RSUs, with an aggregate grant-date fair value for accounting purposes, in accordance with FASB ASC 718, of $75,605. For additional information, see "—Narrative to Director Compensation" below.

(4)Mr. Belinfanti received cash payments totaling $60,000, including $50,000 representing the portion of Mr. Belinfanti's annual retainer fees paid in cash plus $10,000 representing cash fees for Mr. Belinfanti's service as a member of our compensation committee and corporate compliance and governance committee. Pursuant to the Company's Non-Employee Director Fee Deferral Policy, Mr. Belinfanti elected to receive the deferred restricted stock units in lieu of his third and fourth quarter cash retainer fee and amounts for his committee service. Pursuant to his election, in addition to his annual grant, Mr. Belinfanti was granted 6,880 Deferred RSUs, with an aggregate grant-date fair value for accounting purposes, in accordance with FASB ASC 718, of $64,810. For additional information, see "—Narrative to Director Compensation" below.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

***Narrative to Director Compensation***

In 2025, the Compensation Committee reviewed the non-employee director compensation program relative to the compensation peer group. Based on this review, the Committee approved changes to improve market competitiveness, including (i) an increase to the annual equity retainer from $165,000 to $190,000 and (ii) an increase in the additional compensation for the Chairman from $100,000 to $140,000.

Including these changes, our non-employee directors are eligible to receive (i) an annual cash retainer of $100,000 and (ii) a grant of restricted stock units in the amount of $190,000, determined based on the volume-weighted average price of a share of Common Stock as reported by NASDAQ for the 20 days immediately prior to the annual meeting of stockholders of the Company. The restricted stock unit awards granted to our non-employee directors during 2025 are credited with dividend equivalent rights in respect of any cash dividends paid while such restricted stock units are outstanding, which dividend equivalents are subject to the same vesting conditions as the applicable restricted stock units and are paid in cash, without interest, upon settlement of such units. Our non-employee directors are eligible to receive an additional annual retainer for their service as Chairman, and chair or members of certain committees (in cash or as a grant of restricted stock units (determined based on the volume-weighted average price of a share of Common Stock as reported by NASDAQ for the 20 days immediately prior to the date of grant), at the non-employee director's election) in the following amounts:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• $140,000 for our Chairman;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• $40,000 for the chair of our Audit Committee;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• $20,000 for each member of the Audit Committee;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• $20,000 for the chairs of each of the Compensation Committee and Corporate Compliance and Governance Committee; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• $10,000 for each member of the Compensation Committee and Corporate Compliance and Governance Committee.

Effective as of May 30, 2025, the Committee adopted a Non-Employee Director Fee Deferral Policy, which permits non-employee directors to elect, on an annual basis, to receive Deferred RSUs in lieu of their cash retainer fees ("Retainer RSUs") and to defer the settlement of their annual grant of restricted stock units ("Annual Deferred RSUs"). Retainer RSUs vest at the same time as the corresponding cash retainer fees would have been paid absent the election (for 2025, in equal quarterly installments). Annual Deferred RSUs vest at the same time that the applicable non-employee director's annual restricted stock unit award would have vested absent the election (for 2025 grants, upon the 2026 annual meeting of stockholders). All Deferred RSUs are settled within 30 days following the first to occur of (i) a change in control or (ii) the director's termination of service. To elect to receive Deferred RSUs, non-employee directors must submit their deferral elections by the applicable submission deadline specified by the Company in accordance with Section 409A of the Code.

During 2025, each of Mr. Lundberg and Mr. Belinfanti elected to receive both Retainer RSUs and Annual Deferred RSUs. Mr. Lundberg received a total of 29,372 Deferred RSUs with a grant-date value of $276,684, and Mr. Belinfanti received a total of 28,226 Deferred RSUs with a grant-date value of $265,889.

In addition to the above, our non-employee directors are also subject to stock ownership guidelines and holding requirements, as outlined under *"Stock Ownership Guidelines"* in our *"Compensation Discussion & Analysis"*. All non-employee directors covered by the policy are either currently compliant with the policy or expected to be compliant within the required timeframe.

**Pay Ratio Disclosure**

The total compensation of our Chief Executive Officer in 2025 was approximately 231 times the median pay of our full-time and part-time employees.

We identified the median employee by including all W-2 employees as of December 31, 2025 who had received W-2 wages (or W-2 equivalents) during the calendar year. We then used the W-2 data to identify the median employee. We did not make any adjustments to the employee population or pay data in determining the median employee (e.g., no cost-of-living adjustments). For computing the ratio, we calculated such employee's total annual compensation in the same manner in which we calculate total annual compensation for the CEO in the Summary Compensation Table. The total compensation of the median employee was calculated to be $44,368.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

We calculated the pay ratio by comparing our Chief Executive Officer's compensation pursuant to Item 402(c)(2)(x), as detailed in the Summary Compensation Table. We divided this by the median employee's total annual compensation. The ratio is $10,256,240 divided by $44,368, or 231 to 1.

**Pay Versus Performance**

The following table provides information for the fiscal years 2025, 2024, 2023, 2022, and 2021 with respect to the compensation of our principal executive officers ("PEOs"), which includes both our current and former CEOs, the average compensation of our other NEOs, and the performance measures set forth in the table.

---

| | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Principal Executive Officers ("PEOs")**<sup>(1)</sup> | **Principal Executive Officers ("PEOs")**<sup>(1)</sup> | **Principal Executive Officers ("PEOs")**<sup>(1)</sup> | **Principal Executive Officers ("PEOs")**<sup>(1)</sup> | **Principal Executive Officers ("PEOs")**<sup>(1)</sup> | **Principal Executive Officers ("PEOs")**<sup>(1)</sup> | **Principal Executive Officers ("PEOs")**<sup>(1)</sup> | **Principal Executive Officers ("PEOs")**<sup>(1)</sup> | | | **Value of Initial Fixed <br> $100 Investment <br> Based on:** | **Value of Initial Fixed <br> $100 Investment <br> Based on:** | **Net** <br> **Income (Loss)**<sup>(5)</sup><br>**($MM)** | **Company** <br> **Selected** <br> **Measure:** <br> **Adj.** <br> **EBITDA**<sup>(6)</sup><br>**($MM)** |
| | **Summary Compensation <br> Table Total** | **Summary Compensation <br> Table Total** | **Summary Compensation <br> Table Total** | **Summary Compensation <br> Table Total** | **Compensation Actually** <br> **Paid Total**<sup>(3)</sup> | **Compensation Actually** <br> **Paid Total**<sup>(3)</sup> | **Compensation Actually** <br> **Paid Total**<sup>(3)</sup> | **Compensation Actually** <br> **Paid Total**<sup>(3)</sup> | **Average Other** <br> **Non-PEO NEOs**<sup>(2)</sup> | **Average Other** <br> **Non-PEO NEOs**<sup>(2)</sup> | **Value of Initial Fixed <br> $100 Investment <br> Based on:** | **Value of Initial Fixed <br> $100 Investment <br> Based on:** | **Net** <br> **Income (Loss)**<sup>(5)</sup><br>**($MM)** | **Company** <br> **Selected** <br> **Measure:** <br> **Adj.** <br> **EBITDA**<sup>(6)</sup><br>**($MM)** |
|<br>**Fiscal <br>Year** | **Current: <br> Suzanne <br> Foster** | **Former: <br>Richard Barasch** | **Former: <br> Stephen <br> Griggs** | **Former: <br> Luke <br> McGee** | **Current: <br> Suzanne <br> Foster** | **Former: <br> Richard <br> Barasch** | **Former: <br> Stephen <br> Griggs** | **Former: <br> Luke <br> McGee** | **Summary <br> Comp <br> Table <br> Total** | **Comp** <br> **Actually** <br> **Paid** <br> **Total**<sup>(3)</sup> | **Company** <br> **TSR**<sup>(4)</sup> | **Peer** <br> **Group** <br> **TSR**<sup>(4)</sup> | **Net** <br> **Income (Loss)**<sup>(5)</sup><br>**($MM)** | **Company** <br> **Selected** <br> **Measure:** <br> **Adj.** <br> **EBITDA**<sup>(6)</sup><br>**($MM)** |
| **2025** | $10256240 | n/a | n/a | n/a | $9602139 | n/a | n/a | n/a | $3424642 | $3219184 | $27 | $110 | $(66) | $631 |
| **2024** | $8391752 | $2074106 | n/a | n/a | $8347867 | $2060486 | n/a | n/a | $4122211 | $2675520 | $25 | $93 | $95 | $689 |
| **2023** | n/a | $2265183 | $10437819 | n/a | n/a | $2048248 | $1893765 | n/a | $2440283 | $(238940) | $19 | $92 | $(675) | $671 |
| **2022** | n/a | n/a | $4724344 | n/a | n/a | n/a | $4296449 | n/a | $2823510 | $1841864 | $51 | $87 | $73 | $594 |
| **2021** | n/a | n/a | $3935883 | $8061871 | n/a | n/a | $2710254 | $(21022257) | $3348903 | $(523574) | $65 | $109 | $158 | $566 |

---

_____________________

(1)For 2025, our PEO was Ms. Foster. For 2024, our PEOs included both our current CEO, Ms. Foster, and our former interim CEO, Mr. Barasch. For 2023, our PEOs included both our former interim CEO, Mr. Barasch, and our former CEO, Mr. Griggs. For 2022, our PEO was Mr. Griggs. For 2021, our PEOs included both Mr. Griggs and our former CEO, Mr. McGee.

(2)For 2025, our non-PEO NEOs were Messrs. Clemens, Barnhart, Schuster, and Prast. For 2024, our non-PEO NEOs were Messrs. Clemens, Prast, Barnhart, Parnes, and Rietkerk, and Ms. Archbold. For 2023, our non-PEO NEOs were Messrs. Parnes, Clemens, Prast, and Rietkerk. For 2022, our non-PEO NEOs were Messrs. Parnes, Clemens, Joyce and Prast. For 2021, our non-PEO NEOs were Messrs. Parnes, Clemens, Prast and Bunting.

(3)In calculating the "Compensation Actually Paid" ("CAP") amounts reflected in these columns, the fair value or change in fair value, as applicable, of the equity award adjustments included in such calculations were computed in accordance with FASB ASC Topic 718. Stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date of grant. Adjustments have been made using stock option fair values as of each measurement date using the stock price as of the measurement date and updated assumptions as of the measurement date. Time-vested restricted stock/unit grant date fair values are calculated using the stock price as of date of grant. Adjustments have been made using the stock price as of year-end and as of each vesting date. Performance-vested restricted stock unit fair values are calculated based on the Monte Carlo valuation model as of the date of grant. Adjustments have been made using performance-vested restricted stock unit fair values as of each measurement date using the stock price as of the measurement date and updated Monte Carlo assumptions. The assumptions used to calculate the fair value for purposes of determining CAP are consistent with the methodology used for calculating the grant date fair value for financial reporting purposes. There are no dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise included in the CAP amounts for the applicable year.

(4)The Company Total Shareholder Return ("TSR") and the Company's Peer Group TSR reflected in these columns for each applicable fiscal year are calculated based on a fixed investment of $100 at the applicable measurement point on the same cumulative basis as is used in Item 201(e) of Regulation S-K. The peer group used to determine the Company's Peer Group TSR for each applicable fiscal year is the S&P Healthcare Services Select Industry Index, which is included in the Company's TSR performance graph in this Proxy Statement.

(5)Represents the amount of net income (loss), as reported in the Company's audited GAAP financial statements for all years included in this table.

(6)We have selected Adjusted EBITDA as our most important financial measure (that is not otherwise required to be disclosed in the table) used to link compensation actually paid to our NEOs to Company performance for fiscal year 2025. Our Compensation Committee determined the 2025 annual bonus outcome for eligible NEOs partially based on the achievement of this measure, which was adjusted for a litigation settlement expense that was approved by the Committee for purposes of determining Adjusted EBITDA for payment of the 2025 annual incentive for the

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

Company's NEOs. See the section titled "Year in Review and Alignment of Company Performance with Pay" on page <u>[23](#icb8b7d474fb54376885edd8b3dcbbb72_49)</u> of this Proxy Statement for additional information.

In the calculation of CAP presented in the table, the following amounts were deducted and added:

***Reconciliation of Summary Compensation Table ("SCT") total to Compensation Actually Paid ("CAP")***

---

| | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **FY2025** | **FY2025** | **FY2024** | **FY2024** | **FY2024** | **FY2023** | **FY2023** | **FY2023** | **FY2022** | **FY2022** | **FY2021** | **FY2021** | **FY2021** |
| **Description of Elements Added / Subtracted to SCT Total to Calculate CAP** | **Description of Elements Added / Subtracted to SCT Total to Calculate CAP** | **Current <br> PEO <br> Foster** | **Average <br> Other <br> NEOs** | **Current <br> PEO <br> Foster** | **Former <br> PEO <br> Barasch** | **Average <br> Other <br> NEOs** | **Former <br> PEO <br> Barasch** | **Former <br> PEO <br> Griggs** | **Average <br> Other <br> NEOs** | **Former <br> PEO <br> Griggs** | **Average <br> Other <br> NEOs** | **Former <br> PEO <br> Griggs** | **Former <br> PEO <br> McGee** | **Average <br> Other <br> NEOs** |
| **Summary Compensation Table ("SCT") Total** | **Summary Compensation Table ("SCT") Total** | $**10256240** | $**3424642** | $**8391752** | $**2074106** | $**4122211** | $**2265183** | $**10437819** | $**2440283** | $**4724344** | $**2823510** | $**3935883** | $**8061871** | $**3348903** |
| **-** | Pension and equity amounts reported in SCT | $7530880 | $2221309 | $6592784 | $474408 | $2914398 | $743274 | $7257900 | $1372050 | $3698882 | $1963262 | $2795498 | $5808758 | $2474283 |
| **+** | Fair value of equity compensation granted in current year and outstanding at year end | $6815203 | $2012341 | $6548899 | $— | $1618903 | $186726 | $294606 | $434705 | $3950263 | $2096688 | $1569869 | $— | $1646856 |
| + | Change in fair value of equity granted in prior years that remains outstanding at current year end; reflects fair value at current year end - fair value at prior year end | $94912 | $(5647) | $— | $— | $12040 | $— | $(2179990) | $(1729450) | $(504103) | $(357484) | $— | $— | $(1549939) |
| - | Fair value of awards forfeited in current year valued at prior year end | $— | $— | $— | $— | $184256 | $— | $— | $— | $— | $— | $— | $20840650 | $— |
| **+** | Fair value of equity compensation granted and vested in current year | $— | $— | $— | $391375 | $— | $471798 | $948505 | $— | $— | $— | $— | $— | $— |
| **+** | Change in fair value of equity granted in prior years and vested in current year | $(33336) | $9157 | $— | $69413 | $21020 | $(132185) | $(349275) | $(12428) | $(175173) | $(757588) | $— | $(2434720) | $(1495111) |
| **Compensation Actually Paid ("CAP")** | **Compensation Actually Paid ("CAP")** | $**9602139** | $**3219184** | $**8347867** | $**2060486** | $**2675520** | $**2048248** | $**1893765** | $**(238940)** | $**4296449** | $**1841864** | $**2710254** | $**(21022257)** | $**(523574)** |

---

***Pay Versus Performance Comparative Disclosure***

The following charts reflect the relationships between (i) CAP to our current and former PEOs, and the average of CAP to our non-PEO NEOs, to (ii) our cumulative TSR and our peer group TSR for the same period, our GAAP Net Income (Loss), and Adjusted EBITDA for the fiscal years 2021, 2022, 2023, 2024, and 2025.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

![67992](ahco-20260428_g3.jpg)

![67994](ahco-20260428_g4.jpg)

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

![67997](ahco-20260428_g5.jpg)

_____________________

Note: For all charts above, PEOs are shown separately for the fiscal years in which the executive served in the PEO role, as follows: 2021 for our Former PEO, Mr. McGee ("Former PEO #3"); 2021, 2022, and 2023 for our Former PEO, Mr. Griggs ("Former PEO #2"); 2023 and 2024 for our Former PEO, Mr. Barasch ("Former PEO #1"), and 2024 and 2025 for our current CEO, Ms. Foster (Current PEO). Compensation data is not shown for fiscal years in which the executives were not employed by the Company.

***Pay Versus Performance Tabular List***

The following table lists our most important financial performance measures used to link CAP to our NEOs to company performance for fiscal year 2025.

**<u>Most Important Performance Measures</u>**

Adjusted EBITDA

Free Cash Flow

Relative Total Shareholder Return

Net Revenue

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS**

**Policies and Procedures for Related Party Transactions**

Our board of directors has adopted a written related party transaction policy that sets forth the following policies and procedures for the review and approval or ratification of related party transactions.

A "**Related Party Transaction**" is a transaction, arrangement or relationship in which we or any of our subsidiaries was, is or will be a participant, the amount of which involved exceeds $120,000, and in which any Related Person had, has or will have a direct or indirect material interest. A "**Related Person**" means:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any person who is, or at any time during the applicable period was, one of our officers or directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any person who is known by us to be the beneficial owner of more than 5% of our voting stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any immediate family member of any of the foregoing persons, which means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law of a director, an officer or a beneficial owner of more than 5% of our voting stock, and any person (other than a tenant or employee) sharing the household of such director, officer or beneficial owner of more than 5% of our voting stock; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any firm, corporation or other entity in which any of the foregoing persons is a partner or principal or in a similar position or in which such person has a 10% or greater beneficial ownership interest.

We have policies and procedures designed to minimize potential conflicts of interest arising from any dealings we may have with our affiliates and to provide appropriate procedures for the disclosure of any real or potential conflicts of interest that may exist from time to time. Specifically, pursuant to its charter, the Audit Committee has the responsibility to review related party transactions.

**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The following table sets forth information known to us regarding the beneficial ownership of our Common Stock as of April 24, 2026:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• each person who is the beneficial owner of more than 5% of the outstanding shares of our Common Stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• each of our NEOs and directors; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• all of our current executive officers and directors, as a group.

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security or has the right to acquire securities within 60 days, including options and warrants that are currently exercisable or exercisable within 60 days.

The beneficial ownership of our Common Stock as of April 24, 2026 is based on 136,054,152 shares of Common Stock issued and outstanding in the aggregate as of April 24, 2026.

Unless otherwise indicated, the Company believes that all persons named in the table below have sole voting and investment power with respect to all shares of voting stock beneficially owned by them.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**Beneficial Ownership Table**

---

| | | |
|:---|:---|:---|
| | | **Common Stock** |
| **Name and Address of Beneficial Owner**<sup>(1)</sup> | **# of Shares** | **% of Total** |
| *Directors and Named Executive Officers* |  |  |
| Suzanne Foster<sup>(2)</sup> | 337294 | \* |
| Jason Clemens | 373509 | \* |
| Albert Prast<sup>(3)</sup> | 389549 | \* |
| Russell Schuster | 33002 | \* |
| Toby Scott Barnhart | 50775 | \* |
| Kenneth A. Samet |  |  |
| Gregory Belinfanti<sup>(4)</sup> | 79382 | \* |
| Terence Connors<sup>(5)</sup> | 76263 | \* |
| Dale Wolf<sup>(6)</sup> | 118235 | \* |
| Brad Coppens<sup>(7)(8)</sup> | 77346 | \* |
| David Williams III<sup>(9)</sup> | 45045 | \* |
| Theodore Lundberg<sup>(10)(11)</sup> | 866761 | \* |
| Diana Nole<sup>(12)</sup> | 33045 | \* |
| Dr. Susan Weaver<sup>(13)</sup> | 94818 | \* |
| *Stockholders beneficially owning 5% or more of our Common Stock* |  |  |
| OEP AHCO Investment Holdings, LLC<sup>(14)</sup> | 16312698 | 11.99% |
| Everest Trust<sup>(15)</sup> | 8299879 | 6.10% |
| BlackRock, Inc.<sup>(16)</sup> | 14667181 | 10.78% |
| FMR LLC<sup>(17)</sup> | 7631435 | 5.61% |
| Matthew Ebbel<sup>(18)</sup> | 8580443 | 6.31% |
| The Vanguard Group<sup>(19)</sup> | 11277493 | 8.29% |
| Deerfield Management Company, L.P.<sup>(20)</sup> | 11477730 | 8.44% |
| Reinhart Partners, LLC<sup>(21)</sup> | 7236262 | 5.32% |
| Dimensional Fund Advisors<sup>(22)</sup> | 6920973 | 5.09% |
| All directors and executive officers as a group (17 individuals)<sup>(23)</sup> | 2658320 | 1.95% |

---

_____________________

\*Represents beneficial ownership of less than 1% of our Common Stock.

(1)Unless otherwise noted, the business address of each of the listed entities or individuals is c/o AdaptHealth LLC, 555 East North Lane, Suite 5075, Conshohocken, PA 19428.

(2)Includes 123,466 shares of Common Stock underlying Restricted Stock Units that are scheduled to vest on May 20, 2026.

(3)Includes 180,021 shares of Common Stock underlying options that are currently exercisable.

(4)Includes 21,346 shares of Common Stock underlying Restricted Stock Units that are scheduled to vest on June 18, 2026.

(5)Includes 21,346 shares of Common Stock underlying Restricted Stock Units that are scheduled to vest on June 18, 2026.

(6)Includes 21,346 shares of Common Stock underlying Restricted Stock Units that are scheduled to vest on June 18, 2026.

(7)The business address of Mr. Coppens is c/o InTandem Capital Partners, One Vanderbilt Avenue, 24th Floor, New York, NY 10017.

(8)Includes 21,346 shares of Common Stock underlying Restricted Stock Units that are scheduled to vest on June 18, 2026.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

(9)Includes 21,346 shares of Common Stock underlying Restricted Stock Units that are scheduled to vest on June 18, 2026.

(10)The business address of Mr. Lundberg is 66 Field Point Road, 2nd Floor, Greenwich, CT 06830. Mr. Lundberg and Carlos Ferrer, as managing members of Peloton Equity GP, LLC ("**Peloton Equity GP**"), may be deemed to beneficially own shares held directly by Peloton Equity GP. Includes shares beneficially owned by Peloton Equity GP.

(11)Includes 21,346 shares of Common Stock underlying Restricted Stock Units that are scheduled to vest on June 18, 2026.

(12)Includes 21,346 shares of Common Stock underlying Restricted Stock Units that are scheduled to vest on June 18, 2026.

(13)Includes 21,346 shares of Common Stock underlying Restricted Stock Units that are scheduled to vest on June 18, 2026.

(14)Based upon information reported on the Form 4/A filed with the SEC on March 30, 2026. The business address of OEP AHCO Investment Holdings, LLC is c/o One Equity Partners, 510 Madison Avenue, 19th Floor, New York, NY 10022.

(15)Based upon information reported on the Schedule 13D/A filed with the SEC on June 11, 2024, Section 16 reports filed with the SEC and other information provided to the Company. Includes shares held directly by Clifton Bay Offshore Investments L.P. ("**Clifton Bay Investments**") and Quadrant Management, Inc. ("**QMI**"). The general partner of Clifton Bay Investments is Clifton Bay Management Ltd. ("**Clifton Bay Management**"), which is indirectly owned by the Trustee of the Everest Trust ("**Everest**"), a trust settled by Mr. Wayne Quasha. Q Management Services (PTC) Ltd., as Trustee of Everest Trust, owns all of the shares of Everest Hill Group Inc., which indirectly controls Clifton Bay Management. Vicali Services (BVI) Inc., a British Virgin Islands company ("**Vicali**"), is the sole director of Everest Hill Group Inc. and Q Management, and Susan V. Demers, a United States citizen, and Andrea J. Douglas, a citizen of New Zealand, are the directors of Vicali and each of them has voting power over Vicali and thus power over investment and voting determinations made by Clifton Bay Management. QMI is owned by Everest Hill Group Inc. Mr. Wayne Quasha ultimately beneficially owns all of the shares of Everest Hill Group Inc., and as such, is in a position, indirectly, to determine the investment and voting decisions made by Everest Hill Group Inc. and Clifton Bay Management. The business address of Clifton Bay Investments and Clifton Bay Management is Tropic Isle Building, P.O. Box 3331, Road Town, Tortola, British Virgin Islands VG 1110. The business address of Mr. Wayne Quasha is c/o PFD Corporate Services (BVI) Limited, Tropic Isle Building, P.O. Box 3331, Road Town, Tortola, British Virgin Islands VG 1110. The business address of Everest Hill Group Inc. is Tropic Isle Building, P.O. Box 3331, Road Town, Tortola, British Virgin Islands VG 1110.

(16)Based upon information reported on the Schedule 13G/A filed with the SEC on July 17, 2025. BlackRock, Inc. reported that, as of June 30, 2025, it had sole voting power for 14,413,701 shares of Common Stock and sole dispositive power for 14,667,181 shares of Common Stock, and shared voting and dispositive power for 0 shares of Common Stock. The business address of BlackRock, Inc. is 50 Hudson Yards, New York, NY 10001.

(17)Based upon information reported on the Schedule 13G/A filed with the SEC on February 5, 2026. FMR LLC reported that, as of December 31, 2025, it had sole voting power of 7,626,717 shares of Common Stock and sole dispositive power for 7,631,435.08 shares of Common Stock, and shared voting and dispositive power for 0 shares of Common Stock. Abigail P. Johnson reported shared beneficial ownership over the shares beneficially owned by FMR LLC. The business address of FMR LLC is 245 Summer Street, Boston, MA 02210.

(18)Based upon information reported on the Form 4 filed with the SEC on August 14, 2023. Includes 2,815,117 shares of Common Stock held directly by SkyKnight Aero Holdings, LLC ("**SkyKnight Aero Holdings**"), 5,565,126 shares of Common Stock held directly by SkyKnight Capital Fund II, L.P. ("**SkyKnight Fund II**"), and 200,200 shares of Common Stock held directly by SkyKnight Aero Holdings II, LLC ("**SkyKnight Aero Holdings II**"). SkyKnight Capital, L.P. ("**SkyKnight Capital**"), as manager of SkyKnight Aero Holdings and SkyKnight Aero Holdings II, and SkyKnight Capital Management, LLC ("**SkyKnight Capital Management**"), as the general partner of SkyKnight Capital, may be deemed to beneficially own the shares held directly by SkyKnight Aero Holdings and SkyKnight Aero Holdings II. SkyKnight Capital II GP, LLC ("**SkyKnight II GP**"), as the general partner of SkyKnight Fund II, may be deemed to beneficially own the shares held directly by SkyKnight Fund II. Mr. Ebbel, as the managing member of each of SkyKnight Capital Management and SkyKnight II GP, may be deemed to beneficially own the shares held directly by SkyKnight Aero Holdings, SkyKnight Aero Holdings II, and SkyKnight Fund II. The business address of Mr. Ebbel and SkyKnight Capital is One Letterman Drive, Building C, Suite 3-950, San Francisco, CA 94129.

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

(19)Based upon information reported on the Schedule 13G/A filed with the SEC on October 30, 2025. The Vanguard Group reported that, as of September 30, 2025, it had sole voting power for 0 shares of Common Stock, shared voting power for 742,453 shares of Common Stock, sole dispositive power for 10,404,748 shares of Common Stock and shared dispositive power for 872,745 shares of Common Stock. On March 26, 2026, The Vanguard Group filed a Schedule 13G/A to disclose an internal realignment that occurred on January 12, 2026. Due to the internal realignment, certain subsidiaries or business divisions of subsidiaries of The Vanguard Group that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group. As of March 26, 2026, The Vanguard Group reported that it no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions. The business address of The Vanguard Group is 100 Vanguard Blvd., Malvern, PA 19355.

(20)Based upon information reported on the Schedule 13G/A filed with the SEC on November 13, 2025. Includes 11,457,730 shares of Common Stock held by Deerfield Private Design Fund IV, L.P. and Deerfield Partners, L.P., of which Deerfield Management Company, L.P. is the investment manager, and 20,000 shares of Common Stock held by Steven Hochberg, an operating partner of Deerfield Management Company, L.P., for the benefit, and subject to the direction, of Deerfield Management Company, L.P. James E. Flynn reported shared beneficial ownership over the shares beneficially owned by Deerfield Management Company, L.P. Does not include 12,406,002 shares of Common Stock issuable upon conversion of shares of B-1 Convertible Preferred Stock held by Deerfield Private Design Fund IV, L.P. and Deerfield Partners, L.P. The terms of the Series B-1 Convertible Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Common Stock then outstanding (the "Ownership Cap"). The business address of Deerfield Management Company, L.P. is 345 Park Avenue South, 12th Floor, New York, NY 10010.

(21)Based upon information reported on the Schedule 13G filed with the SEC on May 15, 2025. Reinhart Partners, LLC. reported that, as of March 31, 2025, it had sole voting power for 6,576,074 shares of Common Stock, shared voting power for 0 shares of Common Stock, sole dispositive power for 7,236,262 shares of Common Stock and shared dispositive power for 0 shares of Common Stock. The business address of Reinhart Partners, LLC. is 11090 N. Weston Drive Meequon, WI 53092.

(22) Based upon information reported on the Schedule 13G filed with the SEC on April 9, 2026. Dimensional Fund Advisors LP reported that, as of March 31, 2026, it had sole voting power for 6,793,155 shares of Common Stock, shared voting power for 0 shares of Common Stock, sole dispositive power for 6,920,973 shares of Common Stock and shared dispositive power for 0 shares of Common Stock. The business address of Dimensional Fund Advisors LP is 6300 Bee Cave Road, Building One, Austin, TX 78746.

(23)Includes directors, director nominees and current executive officers.

The following table sets forth information regarding the shares to be issued and the shares remaining available for issuance under our stock-based incentive plans as of December 31, 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Plan category** | **Number of<br>securities to<br>be issued upon<br>exercise of<br>outstanding<br>options, warrants<br>and rights)** | | **Weighted-average<br>exercise price of<br>outstanding<br>options, warrants<br>and rights** | **Securities<br>remaining<br>available for<br>future issuance<br>under equity<br>compensation<br>plans** |
| Equity compensation plans approved by security holders |  |  |  |  |
| &nbsp;&nbsp;&nbsp;*A&R 2019 Stock Incentive Plan* | 5699550 | (1) | $7.24 | 8165473 |
| &nbsp;&nbsp;&nbsp;*2019 Employee Stock Purchase Plan* |  |  |  | 494604 |
| Equity compensation plans not approved by security holders | 659526 | (2) |  |  |
| **Total** | 6359076 |  | $7.24 | 8660077 |

---

(1)The number of issuable securities under the A&R 2019 Plan represents the total number of issued and outstanding stock options (including stock options to purchase 944,829 shares of Common Stock assumed and converted in connection with the acquisition of AeroCare Holdings, Inc. on February 1, 2021, with a weighted-average exercise price of $7.24 per share), and service-based and performance-based restricted stock units (assuming such performance-

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

based restricted stock unit awards are earned at 200% of target). In accordance with SEC guidance, this number does not include issued and outstanding shares of restricted stock.

(2)This number represents the total number of service-based and performance-based restricted stock units (assuming such performance-based restricted stock unit awards are earned at 200% of target) granted to Suzanne Foster outside of the A&R 2019 Plan as an inducement material to Ms. Foster's acceptance of employment with the Company in compliance with and in reliance on Nasdaq Listing Rule 5635(c)(4).

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**SOLICITATION OF PROXIES**

We will bear the cost of soliciting proxies for the Annual Meeting. In addition to solicitations by mail, we may, through our directors and officers, solicit proxies in person, by telephone or by electronic means. Such directors and officers will not receive any special remuneration for these efforts.

**DELINQUENT SECTION 16(a) REPORTS**

Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who beneficially own, or are part of a group that owns, more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership with the SEC. To the Company's knowledge, based solely on our review of such reports filed with the SEC, and written representations from directors and executive officers in D&O questionnaires that all Section 16(a) reports required to be filed for such persons had been filed, we believe that no director, officer or beneficial owners of more than 10% of our total outstanding shares of Common Stock failed to file the reports required by Section 16(a) of the Exchange Act on a timely basis during the fiscal year ended December 31, 2025, with the following exception: Daniel McFadden (late on one Form 3, upon his appointment as executive officer).

**HOUSEHOLDING INFORMATION**

Unless we have received contrary instructions, we may send a single copy of the Notice, this proxy statement or our Annual Report on Form 10-K to any household at which two or more stockholders reside if we believe the stockholders are members of the same family. This process, known as "**householding**," reduces the volume of duplicate information received at any one household and helps to reduce our expenses. However, if stockholders prefer to receive multiple sets of proxy materials at the same address this year or in future years, the stockholders should follow the instructions described below. We will promptly deliver such additional sets of proxy materials to stockholders who so request. Similarly, if an address is shared with another stockholder and together both of the stockholders would like to receive only a single set of proxy materials, the stockholders should follow these instructions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If the shares are registered in the name of the stockholder, the stockholder should contact us at (i) (610) 424-4515 or (ii) at AdaptHealth LLC, 555 East North Lane, Suite 5075, Conshohocken, PA 19428, Attention: Secretary, to inform us of his or her request; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If a bank, broker or other nominee holds the shares, the stockholder should contact the bank, broker or other nominee directly.

**STOCKHOLDER PROPOSALS AND NOMINATIONS**

Stockholder proposals may be included in our proxy statement for an annual meeting so long as they are provided to us on a timely basis and satisfy the other conditions set forth in SEC regulations under Rule 14a-8 regarding the inclusion of stockholder proposals in company-sponsored proxy materials. For a stockholder proposal to be considered for inclusion in our proxy statement for our annual meeting of stockholders to be held in 2027, we must receive the proposal at our principal executive offices at AdaptHealth LLC, 555 East North Lane, Suite 5075, Conshohocken, PA 19428, Attention: Secretary, not earlier than February 18, 2027 and not later than March 20, 2027. In addition, a director nomination or a stockholder proposal of other business for consideration at our 2026 annual meeting that is not intended for inclusion in our proxy statement under Rule 14a-8 may be brought before our 2027 annual meeting so long as we receive information and notice of the nomination or proposal in compliance with the requirements set forth in our bylaws at our principal executive offices not later than the close of business on the 90th day nor earlier than the close of business on the 120th day before the anniversary date of the immediately preceding annual meeting of stockholders; provided, however, that in the event that the date of the 2027 annual meeting is more than 30 days before or more than 70 days after such anniversary date, such nomination proposal must be received at our principal executive offices not earlier than the close of business on the 120th day before the 2026 annual meeting and not later than (x) the close of business on the 90th day before the 2027 annual meeting or (y) the close of business on the 10th day following the day on which public announcement of the date of the 2027 annual meeting is first made by the Company. In addition, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than April 19, 2027.

**COMMUNICATIONS WITH THE BOARD**

Stockholders and other interested parties wishing to communicate with the board of directors or with an individual board member concerning the Company may do so by writing to the board or to the particular board member and mailing the correspondence to our principal executive offices to the attention of our Secretary. If from a stockholder, the envelope

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

should indicate that it contains a stockholder communication. All such communication will be forwarded to the director or directors to whom the communications are addressed.

**AVAILABLE INFORMATION**

We will provide to any stockholder entitled to vote at our Annual Meeting, at no charge, a copy of our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 24, 2026, including the financial statements and the financial statement schedules contained in the Form 10-K. Our Annual Report on Form 10-K and our other filings with the SEC are available to the public through the SEC's website at https://www.sec.gov and are also available through our website at https://www.adapthealth.com/investorrelations. You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information on our website does not constitute part of this proxy statement. You may request a copy of the Annual Report on Form 10-K or additional copies of this proxy statement at no cost in writing or by telephone at the following address and phone number:

AdaptHealth LLC

555 East North Lane, Suite 5075

Conshohocken, PA 19428

Attention: Secretary

Telephone: (610) 424-4515

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

**Proxy Card**![1776960305416-843214c4-5e06-45a1-99db-4f3dc8e67394_1__PROXY CARD PAGE 1.jpg](ahco-20260428_g6.jpg)

------

[**TABLE OF CONTENTS**](#icb8b7d474fb54376885edd8b3dcbbb72_10)

![1776960733440-11ba798b-1f09-4361-a84e-cf2915afc4a6_1__PROXY CARD PAGE 2.jpg](ahco-20260428_g7.jpg)